The QualityStocks Daily Wednesday, April 27th, 2022

Today's Top 3 Investment Newsletters

QualityStocks(AFIB) $1.0900 +36.00%

MarketClub Analysis(ARLP) $18.1600 +14.86%

TradersPro(SJT) $11.1071 +13.26%

The QualityStocks Daily Stock List

Ardmore Shipping (ASC), MarketBeat, StreetInsider, Daily Trade Alert, Vantage Wire, Trades Of The Day, Barchart, Market Report, Investing Daily, Investiv, StockMarketWatch, Zacks, Streetwise Reports, TopStockAnalysts, VectorVest, Wealth Insider Alert and QualityStocks reported earlier on Ardmore Shipping (ASC), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Ardmore Shipping Corporation (NYSE: ASC) (FRA: A61) is a holding firm that is engaged in the operation and ownership of chemical and product tankers.

The firm has its headquarters in Pembroke, Bermuda and was incorporated in 2013, on May 14th by Anthony Gurnee. It operates as part of the industrials sector, in the industrial services industry, under the transportation and logistics sub-industry and serves consumers across the globe.

The company is building a talented and motivated staff of shipping professionals who are committing to offering the highest standard of corporate management, operations and customer service. It has more than 30 subsidiaries, including Ardmore Shipping LLC, Ardmore Shipping Pte. Ltd, Ardmore Shipping Services Ltd and Ardmore Shipping Ltd. which operate in the Americas, Asia, Ireland and Bermuda respectively.

The enterprise provides seaborne transportation of chemicals and petroleum products as well as providing shipping services to consumers through time charters, commercial pools and voyage around the world. It serves pooling service providers, chemical companies, chemical and oil traders, oil companies and oil majors. The enterprise’s fleet is made up of more than twenty chemical and double-hulled product tankers, all of which are in operation. Its vessels include the Sealeader, the Seamaster, the Seatrader, the Seafarer, the Endeavour, the Seahawk, the Seafox, the Sealion, the Seacanguard, the Seavantage, the Seaventure and the Seavaliant, which all have the prefix Ardmore in their names.

The company recently announced its Energy Transition Plan which centers on three main areas. The plan, which is an extension of its current strategy, will build on the company’s core strengths and facilitate its growth as it achieves its objectives.

Ardmore Shipping (ASC), closed Wednesday's trading session at $6.33, up 12.8342%, on 684,805 volume. The average volume for the last 3 months is 679,143 and the stock's 52-week low/high is $3.0699/$6.44.

Acutus Medical (AFIB)

MarketBeat, QualityStocks, Trades Of The Day, StreetInsider, Daily Trade Alert and BUYINS.NET reported earlier on Acutus Medical (AFIB), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Acutus Medical Inc. (NASDAQ: AFIB) is a medical device firm that is focused on designing, manufacturing and marketing various tools for catheter-based procedures for the treatment of different arrhythmias.

The firm has its headquarters in Carlsbad, California and was incorporated in 2011 by Christoph Scharf and Randell L. Werneth. It operates as part of the medical equipment and supplies manufacturing industry, under the healthcare sector. The firm has three companies in its corporate family. It serves consumers around the globe, with a focus on Europe and the United States.

The company develops electrophysiological mapping systems for the treatment of cardiac arrhythmias, like ventricular tachycardia and atrial fibrillation. It sells and markets its electrophysiology products globally to electrophysiologists and hospitals that treat arrhythmia patients.

The enterprise’s product portfolio comprises of its AcQMap mapping and imaging system, which is made up of a single-use catheter, software algorithms, workstation and a console. It has been designed to enhance outcomes and procedure efficiency by identifying ablation targets accurately and confirming procedure completion and ablation success. This system offers unmatched precision and speed. In addition to this, the enterprise also provides conventional and contact force ablation catheters, diagnostic and mapping catheters, transseptal crossing tools, new access sheaths, software programs and supporting algorithms.

The company is focused on launching new products, reshaping the field of electrophysiology and realizing its strategy to become the partner of choice to electrophysiologists through its differentiated and broad portfolio of imaging, diagnostic, access and therapy products.

Acutus Medical (AFIB), closed Wednesday's trading session at $1.09, up 35.995%, on 72,190,002 volume. The average volume for the last 3 months is 72.19M and the stock's 52-week low/high is $0.7605/$18.00.

Eyenovia Inc. (EYEN)

MarketBeat, StreetInsider, QualityStocks, StockMarketWatch, Trading Concepts, TradersPro, Daily Trade Alert, MarketClub Analysis and BUYINS.NET reported earlier on Eyenovia Inc. (EYEN), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Eyenovia Inc. (NASDAQ: EYEN) is a clinical stage biopharmaceutical firm that is focused on the development of its MAP (microdose array print) platform technology.

The firm has its headquarters in New York and was incorporated in 2014, on March 12th by Sean Ianchulev. Prior to its name change in May 2014, the firm was known as PGP Holdings V. Inc. It operates as part of the pharmaceutical and medicine manufacturing industry, under the healthcare sector. The firm serves consumers in the United States.

The company is party to a license agreement with Arctic Vision Ltd, which entails the development and commercialization of MicroLine and MicroPine in South Korea and China. It is also party to a license agreement with Bausch Health Ireland Ltd, which involves the development and commercialization of MicroPine in Canada and the United States.

The enterprise’s pipelines are focused on developing therapeutic indications for patients with presbyopia indications, progressive myopia or age-related near vision impairment. Its product portfolio is comprised of MicroPine, which has been developed to treat pediatric myopia progression. It also develops MicroLine, which has been developed to improve near vision in individuals with presbyopia. In addition to this, the enterprise develops MydCombi, which has indications for pharmaceutical mydriasis.

The company recently announced its operating and financial results for its second quarter of 2021, which highlight positive topline data from its MicroLine phase 3 clinical trial. Currently, the company is focused on advancing its MydCombi formulation, which it believes holds the potential to become a standard of care for comprehensive eye exams.

Eyenovia Inc. (EYEN), closed Wednesday's trading session at $2.56, up 8.0169%, on 302,497 volume. The average volume for the last 3 months is 302,497 and the stock's 52-week low/high is $2.28/$6.63.

Elevation Oncology (ELEV)

Actual Gains,, QualityStocks, OTCPicks, Buzz Stocks, FeedBlitz, HEROSTOCKS, Liquid Pennies, MarketBeat, PennyTrader Publisher, WhisperFromWallStreet, SmallCapStockPlays, Stock Brain, Stock Exploder,, VIP STOCK ALERTS and Otcstockexchange reported earlier on Elevation Oncology (ELEV), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Elevation Oncology Inc. (NASDAQ: ELEV) is a clinical-stage biopharmaceutical firm that is engaged in the development of therapeutics for treating cancer in genomically-defined patient populations.

The firm has its headquarters in New York and was incorporated in 2019 by Shawn M. Leland. It serves consumers in the United States.

The company’s objective is to introduce new targeted therapies for patients with cancer as well as illuminate what the company is doing to create a future where every patient can receive care built around targeting their unique tumor drivers and understanding. This will be done by having every tumor’s unique genomic test result matched with a purpose-built precision medicine that will allow the use of individualized treatment plans for patients.

The enterprise’s formulations identify and target inhibition of tumor-specific drive alterations. Its product portfolio comprises of an anti-HER3 monoclonal antibody dubbed seribantumab, which is undergoing a phase 2 Crestone trial evaluating its effectiveness in treating advanced solid tumors that harbor neuregulin-1 fusions (NRG1 fusions).The NRG1 gene fusions are rare genomic alterations which combine NRG1 with other partner proteins to create a chimeric NRG1 fusion protein. These fusions have been identified in a variety of solid tumors, including cholangio carcinomas, neuroendocrine, colorectal, ovarian, breast, gallbladder, pancreatic, lung and sarcomas.

The firm is focused on making progress on its mission to bring purpose-built medicines to patients suffering from genomically defined cancers. The success of their formulations will not only address unmet needs in patients but also bring in more investments into the firm.

Elevation Oncology (ELEV), closed Wednesday's trading session at $2.84, up 16.3934%, on 102,105 volume. The average volume for the last 3 months is 102,105 and the stock's 52-week low/high is $2.275/$16.22.

PyroGenesis Canada (PYR)

MarketClub Analysis, Trades Of The Day, StocksEarning, Schaeffer's and QualityStocks reported earlier on PyroGenesis Canada (PYR), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

PyroGenesis Canada Inc. (NASDAQ: PYR) (TSE: PYR) (FRA: 8PY) is an environmental solutions firm that is focused on designing, developing, manufacturing and commercializing advanced plasma systems and processes.

The firm has its headquarters in Montreal, Canada and was incorporated in 1991. The firm has three companies in its corporate family and serves consumers around the globe. It operates through the Mexico, Asian, Europe, United States and Canada geographical segments.

The enterprise provides a process to produce high purity solar-grade and metallurgical grade silicon from quartz known as Purevap; a sustainable process that improves metal recovery from dross targeting known as Drosrite; and a silicon reactor that’s been designed to transform silicon into spherical silicon nanowires and nanopowders for use in Li-ion batteries known as the Purevap Nano silicon reactor. It also offers plasma torches which include SPT plasma torches for use in refrigerant destruction and other substances; and APT high-powered plasma torches to replace fossil fuel burners. In addition to this, the enterprise provides plasma resource recovery systems for waste-to-energy and land-based waste destruction applications; plasma arc chemical warfare agents; plasma arc waste destruction systems for waste destruction on ships; and plasma arc vitrification and gasification. The enterprise serves the environmental, oil and gas, 3D printing, mining, metallurgical and defense industries.

The company recently launched a new zero-carbon emission hydrogen production technology which produces environmentally-friendly hydrogen. This move positions the company for significant growth in the market, especially with the consumption of zero-carbon emission energy expected to increase to 12.5 million tons annually by 2030.

PyroGenesis Canada (PYR), closed Wednesday's trading session at $2.14, up 13.8298%, on 84,591 volume. The average volume for the last 3 months is 84,235 and the stock's 52-week low/high is $1.58/$6.98.

Seacor Marine Holdings (SMHI)

StreetInsider, StockMarketWatch, Real Pennies, Top Pros' Top Picks, QualityStocks and MarketBeat reported earlier on Seacor Marine Holdings (SMHI), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Seacor Marine Holdings Inc. (NYSE: SMHI) (FRA: SQZ) (BMV: SMHI) is engaged in the provision of marine and support transportation services to offshore natural gas and oil facilities.

The firm has its headquarters in Houston, Texas and was incorporated in 1989. It has fifty-seven companies in its corporate family. The firm serves consumers in the following geographical regions: Europe, mainly in the North Sea; Latin America, mainly in Brazil, Mexico and Guyana; the Middle East and Asia; Africa, mainly in West Africa; the United States, mainly in the Gulf of Mexico.

The company operates through the Bareboat Charter and Time Charter segments. The former segment involves support of vessels among customers, where a customer takes responsibility for all risk of operation and all operating expenses. On the other hand, the latter segment provides vessels to customers based on daily rates of hire.

The enterprise offers support to vessels by delivering personnel and cargo to offshore installations like windfarms; handling mooring equipment and anchors needed to tether rigs; carrying and launching equipment utilized in underwater drilling and well installation, inspection, maintenance and repair; assisting in moving equipment to different locations; offering construction and maintenance support; and providing accommodations for specialists and technicians.

The firm is focused on achieving its ESG goals by aligning its strategy with its focus on environmental sustainability. It is making operational changes that minimize its impact on the environment and investing in green technologies, which is not only good for the environment but will also bring in more investors into the firm, which will have a positive influence on its growth.

Seacor Marine Holdings (SMHI), closed Wednesday's trading session at $7.35, up 10.5263%, on 62,232 volume. The average volume for the last 3 months is 62,134 and the stock's 52-week low/high is $3.08/$8.54.

LianBio (LIAN)

The Online Investor, QualityStocks and MarketBeat reported earlier on LianBio (LIAN), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

LianBio (NASDAQ: LIAN) is a biopharmaceutical firm that is focused on the development and commercialization of medications for the treatment of inflammatory, cardiovascular, ophthalmology, respiratory and oncology ailments.

The firm has its headquarters in Princeton, New Jersey and was incorporated in 2019. The firm serves consumers around the globe, with a focus on the United States, China and other Asian countries.

The company is party to a partnership with Nanobiotix S.A., which entails the development and commercialization for a radiosensitizer dubbed NBTXR3, which is designed to be injected into a malignant tumor before standard radiotherapy. It is also party to a partnership with Tarsus Pharmaceuticals Inc., which involves the development and commercialization of an eye solution known as TP-03, to treat Demodex blepharitis.

The enterprise’s product portfolio is made up of NH-13 for the treatment of ulcerative colitis; a formulation known as BBP-398 for the treatment of solid tumors; LYR-210 for chronic rhinosinusitis; a formulation known as infigratinib for first-line and second-line cholangio carcinoma; a formulation dubbed sisunatovir for the treatment of respiratory syncytical virus; and Omilancor for Crohn’s disease. It is also involved in the development of mavacamten, to treat heart failure with preserves ejection fraction, and non-obstructive and obstructive hypertrophic cardiomyopathy.

The firm’s Infrigratinib formulation recently received approval from the Hainan Province’s Health Commission and Medical Products Administration, for the treatment of metastatic cholangio carcinoma. This move brings the firm one step closer to addressing unmet patient needs, which will benefit the patients and have a positive influence on its growth.

LianBio (LIAN), closed Wednesday's trading session at $5.045, up 8.03%, on 446,209 volume. The average volume for the last 3 months is 446,209 and the stock's 52-week low/high is $2.605/$16.37.

Portage Biotech (PRTG)

MarketBeat reported earlier on Portage Biotech (PRTG), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Portage Biotech, Inc. (NASDAQ: PRTG) is focused on conducting research on and developing biotechnology and pharmaceutical products.

The firm has its headquarters in Tortola, the British Virgin Islands and was incorporated in 1973 by Gregory H. Bailey. It operates as part of the biotechnology industry under the healthcare sector. The firm serves consumers around the globe.

The company identifies and develops first-in-class and best-in-class products and clinical programs which will maximize its potential returns. Its portfolio is made up of subsidiary firms whose technologies and products have established scientific rationales, including virus-like particles, intratumorals, cell penetrating peptides and liposomes.

The enterprise’s product pipeline comprises of a blood-conditioning technology dubbed SBI-101, which restores balance to the immune system after an individual experiences acute injuries to their vital organs; a cell permeable peptide platform known as CellPorter, which is based on human proteins; and an ophthalmic solution dubbed PPL-003. It also develops a formulation dubbed INT230-6, which is undergoing phase II trials looking into its effectiveness in treating solid tumors; a PLGA-nanoparticle combined with an NY-ESO-1 peptide vaccine dubbed IMM65; and an iNKT cell activator known as IMM60. The enterprise also develops a small molecule known as Sting, which has been designed to bind to the interferon gene stimulator in cancer.

The firm, which recently released its latest financial results, remains focused on accelerating its lead clinical programs in an effort to execute its unique drug development strategy. This will bring in more growth opportunities into the firm and positively influence investments as well.

Portage Biotech (PRTG), closed Wednesday's trading session at $5.98, up 11.985%, on 48,357 volume. The average volume for the last 3 months is 47,220 and the stock's 52-week low/high is $4.62/$44.9763.

KemPharm (KMPH)

Schaeffer's, MarketBeat, StockMarketWatch, QualityStocks, Barchart, TraderPower, StreetInsider, Trading Concepts, Streetwise Reports, StocksEarning,, Investing Futures, Market Report and BUYINS.NET reported earlier on KemPharm (KMPH), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

KemPharm Inc. (NASDAQ: KMPH) (FRA: 1GDA) is a specialty pharmaceutical firm that is focused on the discovery and development of different proprietary pro-drugs for the treatment of severe medical indications.

The firm has its headquarters in Celebration, Florida and was incorporated in 2006, on October 30th. It operates as part of the pharmaceutical and medicine manufacturing industry, under the healthcare sector. The firm has three companies in its corporate family and serves consumers in the United States.

The company engages in discovery and development of therapies for treating a myriad of indications. It is party to a number of collaboration and license agreements with Commave Therapeutics SA and KVKTech Inc. The company uses its Ligand Activates Therapy technology to develop improved versions of drugs which have already been approved by the FDA.

The enterprise’s candidate pipeline focuses on high need areas of central nervous system rare illnesses, stimulant use disorder and ADHD (attention deficit hyperactivity disorder). It comprises of a pro-drug candidate dubbed KP879, which has been developed to treat stimulant use disorder; and its KP1077 formulation which is undergoing phase 2 clinical trials testing its efficacy in treating narcolepsy and idiopathic hypersomnia. The KP1077 candidate is based on a d-methylphenidate pro-drug dubbed serdexmethylphnidate.

The company is currently focused on advancing the development of its KP1077 formulation. The success and approval of this formulation by the FDA for the treatment of idiopathic hyperinsomnia will not only bring in additional investments and revenues into the company but also bolster the company’s growth.

KemPharm (KMPH), closed Wednesday's trading session at $4.4, off by 1.0124%, on 418,097 volume. The average volume for the last 3 months is 418,097 and the stock's 52-week low/high is $4.10/$15.6967.

Immunovant Inc. (IMVT)

MarketBeat, StreetInsider, Schaeffer's and Early Bird reported earlier on Immunovant Inc. (IMVT), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Immunovant Inc. (NASDAQ: IMVT) is a clinical-stage biopharmaceutical firm that is focused on the development of monoclonal antibodies for the treatment of autoimmune illnesses.

The firm has its headquarters in New York and was incorporated in 2018. It operates as part of the pharmaceutical and medicine manufacturing industry, under the healthcare sector. The firm has seventeen companies in its corporate family and serves consumers around the globe.

The company’s vision is to enable individuals living with autoimmune illnesses to live normal lives. Autoimmune illnesses usually occur when the immune system of an individual is not able to differentiate between the body’s healthy tissues and harmful pathogens. These illnesses usually target broader bodily systems as well as certain organs. It operates as a subsidiary of Roivant Sciences Ltd.

The enterprise’s pipeline consists of its a new, fully human monoclonal antibody which has been designed to target FcRn (the neonatal fragment crystallizable receptor). This investigational product candidate, dubbed IMVT-1401, is undergoing phase II clinical trials evaluating its effectiveness in treating thyroid eye disease and myastenia gravis. The formulation, which can be self-administered as a subcutaneous injection on a dosing schedule, has already concluded initiation of its phase 2 clinical trials testing its efficacy in treating warm autoimmune hemolytic anemia.

The firm is currently focused on supporting its strategic objectives in order to meet its goals, which will help create shareholder value and bolster the company’s growth, as well as encourage more investments into the company.

Immunovant Inc. (IMVT), closed Wednesday's trading session at $4.61, off by 3.3543%, on 380,874 volume. The average volume for the last 3 months is 380,874 and the stock's 52-week low/high is $4.53/$16.945.


The Street, StreetInsider, The Tycoon Report, The Trading Report, Money Morning, TradingAuthority Daily, The Stock Enthusiast, Street Insider, SmarTrend Newsletters, Money and Markets, MarketBeat, InvestorPlace, Market Report and AllPennyStocks reported earlier on CYNGN Inc. (CYN), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

CYNGN, Inc. (NASDAQ: CYN) is an AV (autonomous vehicle) technology firm which is engaged in the development of autonomous driving software for industrial and commercial machines.

The firm has its headquarters in Menlo Park, California and was incorporated in 2013. Prior to its name change, the firm was known as Cyanogen Inc. It operates as part of the computer systems design and related services industry, under the technology sector. The firm serves consumers in the United States.

The company’s platform uses machine learning, sensor fusion and computer vision to empower vehicles to adjust to complex environments, learn and share, which transforms them into self-driving and fully-integrated fleets of the future.

The enterprise is developing an internal tool suite and infrastructure dubbed CyngnEvolvem which facilitates machine learning and artificial intelligence training to improve models and algorithms. It also offers a simulation framework which ensures that the data gathered in the field can be applied to new releases. It also develops a customer facing tool suite for managing and monitoring autonomous vehicle fleets dubbed Cyngn Insight. This tool also aggregates and analyzes data. In addition to this, the enterprise develops a modular industrial vehicle autonomous driving software known as DriveMod.

The firm recently launched a turnkey autonomous vehicle solution known as the DriveMod Kit for the Stockchaser vehicles. This move creates opportunity for the adoption of the firm’s turnkey solutions for both new and retrofit vehicles, which will help extend its consumer reach and bring in additional revenues.

CYNGN Inc. (CYN), closed Wednesday's trading session at $3.965, up 7.7446%, on 49,997,690 volume. The average volume for the last 3 months is 49.783M and the stock's 52-week low/high is $1.08/$9.91.

Spero Therapeutics (SPRO)

Wall Street Resources, MarketBeat, The Online Investor, StreetInsider, FreeRealTime, Zacks, The Street, Schaeffer's, QualityStocks and DrStockPick reported earlier on Spero Therapeutics (SPRO), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Spero Therapeutics, Inc. (NASDAQ: SPRO) (FRA: 2HA) is a clinical-stage biopharmaceutical firm that is engaged in the identification, development and commercialization of treatments for rare illnesses and MDR (multi-drug resistant) bacterial infections.

The firm has its headquarters in Cambridge, Massachusetts and was incorporated in April 2013 by Laurence Rahme and Ankit A. Mahadevia. It operates as part of the biotechnology industry, under the healthcare sector. The firm serves consumers around the world.

The company is party to a license agreement with Vertex Pharmaceuticals Inc., which involves patents associated with an active metabolite dubbed SPR719 and SPR720. It is also party to a collaboration agreement with the Bill and Melinda Gates Medical Research Institute, involving the development of its SPR720 formulation for treating lung infections brought about by Mycobacterium tuberculosis. In addition to this, the company has license agreements with Everest Medicines for the development, manufacture and commercialization of SPR206 in South Korea, Greater China and Southeast Asian nations; and Meiji Seika Pharma Co. Limited, for developing tebipenemHBr.

The enterprise’s product pipeline comprises of an oral antibiotic dubbed SPR720 for non-TB mycobacterial pulmonary disease; a direct acting agent dubbed SPR206 for the treatment of MDR Gram-negative bacterial infections in hospitals; and a carbapenem-class antibiotic dubbed tebipenemHBr, for the treatment of urinary tract infections.

The company is currently focused on getting its tebipenemHBr formulation, which recently completed a New Drug Application trial, approved by the FDA for use in treating urinary tract infections. The approval of this drug will bring in significant revenue into the company, helping generate shareholder value.

Spero Therapeutics (SPRO), closed Wednesday's trading session at $4.99, off by 4.9524%, on 157,962 volume. The average volume for the last 3 months is 157,962 and the stock's 52-week low/high is $4.96/$19.87.

The QualityStocks Company Corner

Golden Matrix Group Inc. (NASDAQ: GMGI)

The QualityStocks Daily Newsletter would like to spotlight Golden Matrix Group Inc. (NASDAQ: GMGI).

Golden Matrix Group (NASDAQ: GMGI), a developer and licensor of online gaming platforms, systems and gaming content, has gone live with GMX-Ag, its proprietary B2B aggregate gaming system. According to the announcement, the system has eight established online casino operators in six countries. The seamless turnkey iGaming system features the best casino, sportsbook and live-gaming content available through a single integration with the operators’ existing business systems; GMX-Ag also provides a single wallet for players. “The adoption of the GMX-Ag system is both strategic and timely,” said Golden Matrix CEO Brian Goodman in the press release. “It expands our B2B offerings to operators in the Asia Pacific (“APAC”) region, our traditional market, and at the same time opens new market opportunities for Golden Matrix outside of APAC. In addition to enhancing organic growth, we are focused on entering new international markets through the acquisition of B2B and B2C businesses with strong revenues and profitability. We expect our growth strategy to expand the GMGI brand and accelerate the company’s global market penetration.” To view the full press release, visit

Golden Matrix Group Inc. (NASDAQ: GMGI), based in Las Vegas, Nevada, is an established gaming technology company that develops and owns online gaming IP and builds turnkey online casino solutions for gaming operators as well as configurable and scalable white-label gaming platforms for international customers, located primarily in the Asia-Pacific region. GMGI’s gaming IP includes tools for marketing, acquisition, retention and monetization of users. The company’s platform can be accessed through both desktop and mobile applications.

GMGI’s sophisticated software automatically declines any gaming or redemption requests from within the United States, in strict compliance with U.S. law.

Golden Matrix, through a subsidiary, also runs a pay-to-enter prize competition in the United Kingdom and Ireland.

The company’s shares began trading on the Nasdaq under the symbol ‘GMGI’ on March 17, 2022. Golden Matrix shares were previously traded on the OTCQX Best Market.

For the quarter ended January 31, 2022, the company reported revenue of $8.88 million, an increase of 355% over the same quarter one year earlier. Net income for the three-month period was $349,379, up from $52,158 a year earlier. It was the company’s 14th consecutive profitable quarter.

In December 2021, Golden Matrix announced it had entered into a purchase agreement to acquire a controlling ownership interest in UK-based RKingsCompetitions Ltd., one of Ireland’s and the United Kingdom’s leading independent online competition companies. RKings presents customers with paid and free entry routes to competitions that offer a range of prizes, including residential properties, luxury and exotic motor vehicles, holiday packages, technology packages and cash. The competitions are currently open only to residents of Ireland and the United Kingdom. Golden Matrix acquired an 80% ownership interest in RKings for cash and stock. The company also secured an option to purchase the remaining 20 percent interest of RKings, subject to certain requirements.

In March 2022, Golden Matrix announced it had applied for a Mexican gaming permit and, once approved, expects to offer online gaming in Mexico as well as roll out the RKings tournament business globally.


Golden Matrix Group develops fully operational online casino turnkey solutions as well as highly modular, configurable and scalable gaming platforms for its international customers in an effort to promote user acquisition, engagement, retention and monetization. The provided white label gaming platform is unparalleled in both mobile and desktop website deployment, proving compatible throughout all major operating systems and web browsers. In addition, the platform enhances the client’s ability to cater to various gaming scenarios including but not limited to transaction management and a range of loyalty and reward programs. Moreover, user engagement is optimized through the ability to accommodate both free and paid games.

The company’s GM-X System (and recently its next generation GM-Ag System) is considered the industry standard, granting access to over 10,000 games from more than 25 game providers. Through the GM-X System, Golden Matrix offers the industry’s most extensive game portfolio. The company’s gaming partners dominate the global online gaming market to deliver innovative games and premium brand titles. The GM-X System offers payment gateways that integrate with third party platforms or digital wallets. It supports all major currencies and offers multiple language options. The system’s data analytics provide the operator with a 360-degree view of the gaming platform’s performance.

GMGI currently supports over 500 unique casino brands and over 6 million players.

Market Outlook

Online gaming and sports betting sites and apps are increasingly taking market share from traditional location-based casinos. Widespread internet service availability and increasing use of mobile phones for playing online games from homes and public places is driving the market, according to a report from Grand View Research. In addition, factors such as easy access to online gambling, legalization and cultural approval, corporate sponsorships, and celebrity endorsements are also contributing to market growth. The growing availability of cost-effective mobile applications across the globe is further expected to fuel market growth.

This trend is only expected to accelerate as millennials reach their peak earning years and Gen Z youth begin to complete their education and move into careers. These generations are completely comfortable with online recreation, and with using technology like digital wallets and digital gameplay that underpins online gaming.

The global online gambling market was valued at $53.7 billion in 2019 and is expected to grow at a CAGR of 11.5% from 2020 to 2027 to reach a value of $127.3 billion, according to Grand View Research, with much of the growth expected from the U.S. and Asia. Even Europe, the most mature gaming market, is expected to grow at a rate of 20-25% year-over-year.

Management Team

Brian Goodman is CEO of Golden Matrix Group. He has more than 20 years of diverse senior management experience and business development roles within the technology and internet gaming industries. He has a tertiary science qualification as well as a marketing and sales background. His previous roles have been entrepreneurial and include CEO and senior management positions in smaller organizations, which he founded or in which he held equity, as well as multinational organizations.

Cathy Feng is COO at Golden Matrix. She is a co-founder of GMGI and holds a Master of Commerce degree. She has 10 years of experience as a financial officer in the technology and internet gaming industries. In past management positions, she interpreted, analyzed and presented financial and operation information to facilitate business decisions, grow companies and resolve complex problems. In addition, she has skills in marketing, business development, leadership and strategic planning.

Omar Jimenez is CFO and Chief Compliance Officer at GMGI. Prior to joining the company, he was CFO and COO of Alfadan Inc., a supplier of marine outboard engines. He has held senior financial management and operational positions at public and private companies including NextPlay Technologies, American Leisure Holdings, US Installation Group and Onyx Group. He holds various accounting professional certifications, including CPA and CPCU, and degrees in finance, accounting and business.

Henry Zhang is Chief Technology Officer at Golden Matrix. He oversees all aspects of development, integration and deployment of GMGI’s technology systems. He plays a key role in evolving GMGI’s technology business to lead and shape the industry. He is responsible for developing and scaling new businesses, including online gaming, eSport and P2P Systems. He was instrumental in launching the GM-X system and has been with the company for more than six years.

Golden Matrix Group Inc. (NASDAQ: GMGI), closed Wednesday's trading session at $4.81, off by 3.4137%, on 44,208 volume. The average volume for the last 3 months is 44,208 and the stock's 52-week low/high is $4.65/$14.05.

Recent News


The QualityStocks Daily Newsletter would like to spotlight GreenBox POS (NASDAQ: GBOX).

GreenBox (NASDAQ: GBOX), an emerging and rapidly growing fintech company, has appointed Simon & Edward, LLP, as its new registered public accounting firm. The change was effective as of April 19, 2022. GreenBox had previously worked with BF Borgers CPA, and the change was made after the audit committee did a careful evaluation. The company notes that there was no issues or disagreement that prompted the change. Simon & Edward is an independent member of the BDO Alliance USA. “We would like to thank BF Borgers for their professionalism, expertise and guidance during their engagement,” said GreenBox CEO Fredi Nisan in the press release. “The change to Simon & Edward is essential as we prepare for the next stage of our growth and evolution as a public company and indicative of our continued commitment to strong governance practices.” To view the full press release, visit

GreenBox POS (NASDAQ: GBOX) is an emerging financial technology company leveraging proprietary security and token technology to build customized payment solutions for business. The company’s mission is to build compliant, cutting-edge blockchain ledger tokenized solutions for the diverse, evolving and dynamic global market.

GreenBox applications enable an end-to-end suite of turnkey financial products which offer improved fraud detection and better handling efficiency of large-scale commercial payment processing volumes for its merchant clients globally. The company’s proprietary blockchain and smart contract token technologies create seamless payment processing using digital encryption keys.

GreenBox is a unified platform providing scalability for businesses to accept payments, transact, send, settle and convert in a single versatile ecosystem. GreenBox operates a private and proprietary blockchain-based payment platform that offers distinct advantages when compared to traditional payment technologies, including greater security and data privacy, as well as enhanced identity theft protection and quick settlement.

As the settlement engine for financial transactions, GreenBox’s blockchain technology is a distributed ledger that uses digitally encrypted keys to verify, secure and record details of each transaction conducted within GreenBox’s private ecosystem. The speed and security of the platform allows GreenBox to log immense volumes of immutable transactional records in real time for Tier-1 partners around the world.

In November 2021, GreenBox announced the closing of a previously announced $100 million convertible note financing. The company plans to use proceeds for acquisitions, a planned stablecoin spin-off, and additional working capital toward the company’s future growth. The initial conversion price equals a more than 80 percent premium to the market price of the company’s common stock on October 29, 2021, and values the enterprise at more than $700 million upon conversion.

Brands & Solutions

The company offers multiple solutions and brands under the GreenBox label. The other brands that are nested under the GreenBox POS label include coyni, ChargeSavvy, QuickCard, Transact Europe [didn’t yet close] and Northeast Merchant Systems. Each of these brands play a large role in allowing GreenBox to accel in customizing payment solutions across different verticals and industries.

Payment Solutions

The GreenBox platform offers blockchain secure, robust payment processing solutions for both individual consumers and businesses. The company combines the power and security of blockchain with bank-level tools necessary to both settle transactions and monitor cash flows. Customers can transfer cryptocurrencies like USDC, Ethereum or Bitcoin from external decentralized crypto wallets to their GreenBox wallets. They can also exchange those tokens from their GreenBox wallets to any supported coin. Customers can easily offload in USDC to a debit card or a multitude of gift cards.

White Label Solutions

The company’s white label platform allows it to partner with firms seeking blockchain-based tools to manage merchant relationships. White label partners can monitor cash flows, as well as run reports on merchant transactions, chargebacks, agent and affiliate commissions and more. Partners can access the platform through their partner portal to manage business relationships with full visibility. The platform’s cutting-edge technology saves partners time and simplifies their payment processing. It ensures compliance with automated Know Your Customer and Know Your Bank services and allows customers to set up automated payouts.

coyni Stablecoin

The company is planning soon to launch its own stablecoin, coyni (CYN). coyni is equivalent to the value of the U.S. dollar on a one-to-one ratio. Stablecoin allows for instantaneous transactions with blockchain security just like other cryptocurrency tokens, but without the price volatility of traditional cryptocurrencies. The CYN token is expected to make possible features like digital dollar accounts, cross border payments, international payment processing and other payment solutions. As a smart contract technology, coyni will offer instant settlement using the GreenBox blockchain ledger in any location and currency – crypto or fiat – all at lower fees and in a tokenized secure ecosystem.

Market Overview

A Mordor Intelligence report put the transaction value of the global digital payments market at $5.44 trillion in 2020 and projects the market to be worth $11.29 trillion by 2026. That represents a CAGR of 11.21 percent during the period of 2021-2026.

The report notes that the global COVID-19 pandemic and its impact on e-commerce is likely to encourage strengthened international cooperation and further development of policies for online purchasing and supply. The report states, “The pandemic has made it clear that e-commerce can be an important tool/solution, especially considering the fact that e-commerce sales can support small and medium businesses that form the backbone for certain economies. This is expected to substantially spur the growth of digital payment methods across various economies.”

According to Mordor, other drivers of the growth trend in digital payments include:

  • Greater convenience, favorable government policies and evolving consumer behavior worldwide
  • Rapid rise in smartphone penetration throughout emerging economies
  • Introduction of mobile wallets across the world
  • Widespread adoption of retail digital payment services across the vast population of China, serving as a kind of test case for other countries

Management Team

Ben Errez, Chairman of the Board of Directors

Ben Errez’s past positions have included positions at large companies like Microsoft and Intel. He has brought this expertise to lead GreenBox into the forefront of the blockchain-based financial software, services, and hardware market.

Mr. Errez was one of the early managers of Microsoft in 1991. From 1991 to 2004, he served as Software Development Lead for the Microsoft International Office Group. He led the International Microsoft Office Components team (Word, Excel, PowerPoint) in design, engineering, development, and successful deployment. He also served as Executive Representative of Microsoft Office and was a founding member of the Microsoft Trustworthy Computing Team both within the company and internationally. Mr. Errez co-authored the first Microsoft Trustworthy Computing Paper on Reliability. At Microsoft, he was responsible for the development of the first Microsoft software translation Software Development Kit (“SDK”) in Hebrew, Arabic, Thai, and Simplified Chinese, as well as the development of the first bidirectional extensions to Rich Text Format (“RTF”) file format and all bidirectional extensions in text converters for Microsoft Office. He also contributed to the development of the international extensions to the Unicode standard to include bidirectional requirements under the World Wide Web Consortium (“W3C”).

In 2004, Mr. Errez transitioned into the world of consulting, where he held the position of Principal Consultant from founding to the present date, through which he advises clients in the South Pacific region with market capitalizations ranging from $50 million to $150 million on commerce, security, reliability, and privacy.

In 2017, immediately before partnering with Fredi Nisan to launch GreenBox, Mr. Errez was asked to take over the Microsoft Alumni Network for the Southern California region as a regional director. Mr. Errez has been a principal of GreenBox since its inception in 2017.

Fredi Nisan, Chief Executive Officer

Fredi Nisan’s career in technology began during his years of service in the Israeli Defense Forces, where he served as IT Manager for all of Israel’s Northern Bases. After serving in the military, Mr. Nisan opened and operated a computer hardware store before becoming the Inventory Operations Manager for Zicon Israel in 2005, a hardware and software producer. At Zicon, he supervised inventory operations, worked on quality controls for motherboards and chips, and educated customers on software and hardware product functionality. Subsequently, Mr. Nisan moved to the United States, where he worked for One Coach in San Diego, California, as a business coach. One Coach specializes in customized growth solutions for small business owners, including the latest strategies for sales, internet marketing, branding, and ROI. Mr. Nisan was consistently ranked as the top salesperson for small business coaching while working with One Coach.

In 2010, Mr. Nisan launched Brava POS, where he served as President until 2015. Brava POS provided point of sale (“POS”) systems for specialty retail companies. Mr. Nisan developed software to provide clients with solutions for issues ranging from inventory management to payroll to processing high volume transactions in the form of a cloud-based POS system. This system had the capability to manage multiple stores with centralized inventory and process sales without an internet connection, and offered a secure login for each employee, as well as including advanced inventory management and reporting, plus powerful functionality for its end users.

In 2016, Mr. Nisan founded Firmness, LLC. Through Firmness, he created “QuickCitizen,” a software program that simplifies the onboarding process for new clients of law firms specializing in immigration issues. The QuickCitizen software significantly reduced law firms onboarding processing time from more than three hours to approximately 15 minutes. Mr. Nisan has been a principal of GreenBox since its August 2017 inception. In January 2018, Firmness sold QuickCitizen to GreenBox.

Jacquline B. Reynolds, Chief Marketing Officer

Jacqueline B. Reynolds is the company’s Chief Marketing Officer. She served most recently as vice president of marketing for Sprouts Farmers Market. She has built her reputation as a world-class global marketer, working with Coca-Cola, McDonald’s, Verizon, Walmart, L’Oréal, Xbox, 7-Eleven and many other Fortune 500 brands. She has managed award-winning marketing programs with partners such as the NFL, Super Bowl LIV, the Olympics, the FIFA World Cup, Sony Pictures, Universal Music and others.

GreenBox POS (NASDAQ: GBOX), closed Wednesday's trading session at $3.65, up 9.2814%, on 278,001 volume. The average volume for the last 3 months is 278,001 and the stock's 52-week low/high is $2.24/$16.50.

Recent News

Cepton Inc. (NASDAQ: CPTN)

The QualityStocks Daily Newsletter would like to spotlight Cepton Inc. (NASDAQ: CPTN).

Cepton (NASDAQ: CPTN) continues to employ its proprietary LiDAR solutions designed to provide accurate, real-time and anonymized 3D perception, positioning itself to make its mark in the global non-automotive landscape to transform smart cities, spaces and industrial applications. “LiDAR has grown in importance not only for the automotive sector but also for non-automotive applications. The latter includes smart city/infrastructure and security, which are becoming increasingly important for LiDAR producers,” a recent article reads. “As a pioneer in the LiDAR space, Cepton has already been riding the rising non-automotive wave, collaborating with global partners to transform transportation infrastructure, public venues, and large commercial facilities using innovative LiDAR solutions. For example, in 2020, the company partnered with The Indoor Lab in a pilot project at an Orlando International Airport terminal. The aim of the project was to deliver anonymous footfall tracking through a LiDAR-based crowd analytics solution to assist travelers in avoiding crowded areas and maintenance crews in targeted cleaning. In addition, last year, Cepton joined the Qualcomm Smart Cities Accelerator Program in a bid to advance the future of smart infrastructure with their LiDAR systems. And most recently, Cepton engaged in developing a LiDAR-based vehicle detection system to help build city-wide smart transportation infrastructure in South Africa’s Cape Town….” To view the full article, visit

Cepton Inc. (NASDAQ: CPTN) is a provider of state-of-the-art, intelligent, lidar-based solutions serving a range of markets, including automotive (ADAS/AV), smart cities, smart spaces and smart industrial applications. General Motors (NYSE:GM) has granted a series production award for Cepton’s lidar, the biggest such award to date in the automotive space. Cepton’s is the lidar component of GM’s Ultra Cruise autonomous driving platform. By leveraging its patented Micro Motion Technology (MMT®) lidar platform, the company develops reliable, scalable and cost-effective solutions that deliver long-range, high-resolution 3D perception for smart applications.

Cepton was established in 2016 by co-founders Dr. Jun Pei and Dr. Mark McCord. The company is headquartered in San Jose, California, and serves a fast-growing customer base through an international presence spanning North America, Germany, Japan, India and China.

Micro Motion Technology (MMT®)

Cepton was built from the ground up to meet key lidar industry challenges for mass market adoption. This company’s portfolio of proprietary technology is uniquely aimed at facilitating this industry growth through a combination of performance, reliability, affordability and design integration.

Key among its innovations is MMT®, a mirrorless, frictionless, rotation-free 3D imaging platform designed specifically for lidars. Its benefits for OEMs and system integrators include:

  • Reliability – The durable design uses common, easily attainable materials.
  • Versatility – The platform is capable of achieving near- to ultra-long range with a wide field of view.
  • Efficiency – MMT® features a compact form factor, low power usage and inexpensive components.
  • Scalability – Its simple design means that scale-up to high manufacturing volumes is easily attainable.

Because of their compact form factor, Cepton lidars are embeddable and ideally suited for advanced driver-assistance system (ADAS) integration, whether behind windshield, in headlamp or in fascia.

Agreement with KOITO

KOITO Manufacturing Co. Ltd., the world’s premier Tier 1 auto lighting supplier, originally started an evaluation of Cepton’s MMT® based lidars in 2018. In 2020, KOITO made an investment in Cepton aimed at accelerating the company’s development and enabling KOITO’s industrialization of high-performance and high reliability lidar sensors for ADAS and autonomous vehicle (AV) applications.

Through this collaboration, Cepton was able to secure the largest ADAS lidar series production award[1] with General Motors as a sole source in the automotive space. The award covers GM vehicles for the initial period of 2023-2027.

On August 5, 2021, the two companies deepened their relationship when KOITO committed to invest a further $50 million in Cepton’s business through its participation in a Private Investment in Public Equity (PIPE) offering of shares of common stock of Growth Capital Acquisition Corp. in connection with Cepton’s recent merger.

Collaboration with GM

On July 13, 2021, Cepton announced that it had secured an ADAS lidar series production award from a leading, Detroit-based global automotive OEM – the biggest lidar production award by any OEM to any lidar company. It was later clarified that the OEM was General Motors, and Cepton’s lidar is part of GM’s ADAS Ultra Cruise system.

GM is “expected to deploy Cepton lidars in its next generation of advanced driver assistance systems (ADAS) across multiple vehicle classes and models – not just luxury cars.” As such, the agreement marks the potential for “an industry-first, mass-market adoption of lidar technology for automotive ADAS, with an anticipated deployment in consumer vehicles starting in 2023.”

On July 28, 2021, Ford Motor Company (NYSE: F) distributed an article on Medium noting, “Ford has been engaged with Cepton almost since their inception in 2016, both for R&D collaboration and small-scale deployments. Cepton LiDAR are deployed in some of [Ford’s] smart city projects. Based on Ford’s guidance, Cepton delivered a custom version of their LiDAR to enable R&D on advanced ADAS features.”

Market Outlook

Driven by increasing development and adoption in automobile safety applications, environmental mapping and 3D-modeling, the global lidar market is forecast to experience considerable growth over the coming years. A research report published by MarketsAndMarkets suggests that the sector will grow to an estimated $3.4 billion by 2026, achieving a CAGR of 21.6% over the next five years.

The report further highlights increasing investments in lidar startups by automotive giants as a driver of growth opportunities in the sector, particularly in North America.

In 2020, ground-based lidar accounted for the lion’s share of the overall lidar market, and this trend is expected to continue as the automotive sector continues to rapidly advance adoption across the full spectrum of vehicle classes. One factor not to be underestimated is the high barrier of entry and the exceptionally long time required for automotive OEMs to vet and award a production win to a lidar company. It is a commonly held view that the over 50 lidar companies will inevitably coalesce into a handful serving all OEMs.

Cepton, having a head start through its established partnership with leading global OEM GM, is uniquely positioned to capitalize on this market growth in the years to come.

Management Team

Cepton’s founder-led team is made up of lidar industry pioneers with decades of collective experience across advanced lidar and imaging technologies.

Jun Pei, Ph.D., is the company’s CEO and Co-Founder. He is a technology specialist with a focus in optics and electronics. Prior to founding Cepton, Dr. Pei founded AEP Technology, a firm focused on developing advanced 3D optical instruments. He received his Ph.D. in electrical engineering from Stanford University.

Mark McCord, Ph.D., is Cepton’s CTO and Co-Founder. Prior to founding Cepton, he led advanced development at KLA-Tencor. Dr. McCord also formerly served as an associate professor at Stanford University, where he earned his Ph.D. in electrical engineering.

Winston Fu, Ph.D., is the company’s CFO. Dr. Fu is the founder of Silicon Valley venture capital firm LDV Partners. Prior to joining Cepton, he served as CFO and Chairman of Active-Semi before its acquisition. Dr. Fu has also helped to build many technology companies as an entrepreneur and/or board member. He received his Ph.D. in applied physics from Stanford University, as well as an MBA from the Kellogg School of Management at Northwestern University.

[1] Largest known ADAS lidar series production award based on number of vehicle models awarded

Cepton Inc. (NASDAQ: CPTN), closed Wednesday's trading session at $3.07, up 1.6556%, on 250,853 volume. The average volume for the last 3 months is 250,853 and the stock's 52-week low/high is $2.78/$80.16.

Recent News

Lexaria Bioscience Corp. (NASDAQ: LEXX)

The QualityStocks Daily Newsletter would like to spotlight Lexaria Bioscience Corp. (NASDAQ: LEXX).

  • Global drug delivery innovator Lexaria Bioscience is researching the ability of its patented DehydraTECH(TM) technology to improve the performance of a number of prescription drugs 
  • Lexaria is a world leader in the investigation of a DehydraTECH-processed cannabidiol (“CBD”) to potentially treat high blood pressure (hypertension), and study outcomes thus far have rendered positive results on effectiveness and patient tolerance
  • The company is building a scorecard of data to support its planned FDA application for formal, registered clinical testing under the Investigational New Drug (“IND”) process
  • Lexaria recently completed all data analyses of its HYPER-H21-3 study examining DehydraTECH-CBD’s ability to reduce pulmonary artery systolic pressure, and launched HYPER-H21-4 to gather a variety of data points related to DehydraTECH-CBD’s use over a more extensive period of time

High blood pressure has long been labeled “the silent killer” because of its propensity to lead to incapacitating or prematurely deadly strokes, heart attacks and other serious disease indications without necessarily foreshadowing pain or great discomfort. According to the World Health Organization (“WHO”), an estimated 1.28 billion adults aged 30-79 years worldwide have hypertension but only about 1 in 5 (21 percent) people with the condition have it under control with medical treatment ( During the past decade within the United States, about 49 percent of the population reported taking at least one prescription medication in the past 30 days in data sampling collected by the National Center for Health Statistics of the Centers for Disease Control and Prevention at selected times, while 24 percent of the individuals took three or more prescriptions and 13 percent took five or more ( The data showed a marked increase over those persons sampled during the late 1980s to mid-1990s, particularly where multiple medications were concerned. And yet, a recent news report states that as few as 50 percent of patients take their medications exactly as prescribed ( Global drug delivery innovator Lexaria Bioscience (NASDAQ: LEXX) is devoting its research and product development to making drug substances more effective in their approach to treating medical conditions such as high blood pressure and, in the process, to overcoming many of the obstacles that may hinder their proper use by patients. 

Lexaria Bioscience Corp. (NASDAQ: LEXX) is a global innovator in drug delivery platforms. The company’s patented technology, DehydraTECH™, improves the way active pharmaceutical ingredients (APIs) enter the bloodstream by promoting healthier oral ingestion methods and increasing the effectiveness of fat-soluble active molecules.  DehydraTECH promotes fast-acting, less expensive and more effective oral drug delivery and has been thoroughly evaluated through in vivo, in vitro and human clinical testing.

DehydraTECH is covered by 21 issued and more than 50 pending patents in over 40 countries around the world. Lexaria’s first patent was issued by the U.S. Patent and Trademark Office in October 2016 (US 9,474,725 B1), providing 20 years of patent protection expiring June 2034. Multiple patents have been awarded since then and are expected in the future.

Lexaria has a collaborative research agreement with the National Research Council (NRC), the Canadian government’s premier research and technology organization. The company has filed for patent protection for specific delivery of nicotine, vitamins, NSAIDs, testosterone, estrogen, cannabinoids, terpenes, PDE5 inhibitors (with brand names like Viagra), tobacco and more.

Lexaria began developing DehydraTECH in 2014 and has since continued to strengthen and broaden the technology. The company has no plans to create or sell Lexaria-branded products containing controlled substances. Instead, Lexaria licenses its technology to other companies around the world to offer consumers the best possible performance across an array of ingestible product formats.

The company’s technology is best thought of as an additional layer that providers of consumer supplements, prescription and non-prescription drugs, nicotine and CBD products can utilize to improve the effectiveness of their own existing or planned new offerings. Lexaria has licensed DehydraTECH to multiple companies, including a world-leading tobacco producer for the research and development of smokeless, oral-based nicotine products, and for use in industries that produce cannabinoid beverages, edibles and oral products.

DehydraTECH is suitable for use with a wide range of product formats including pharmaceuticals, nutraceuticals, consumer packaged goods and over-the-counter capsules, pills, tablets and oral suspensions.

DehydraTECH Technology

Lexaria’s DehydraTECH is designed specifically for formulating and delivering lipophilic (fat-soluble) drugs and active ingredients. DehydraTECH increases their effectiveness and improves the way active pharmaceutical ingredients enter the bloodstream. The major benefits to a subject ingesting a DehydraTECH-enabled drug or consumer product can be summarized by the following:

  • Speeds up delivery – the effects of the product are felt by the subject in just minutes.
  • Increases bioavailability – the technology is much more effective at delivering a drug or product into the bloodstream.
  • Increases brain absorption – animal testing suggests significant improvement in the quantity of drug delivered across the blood-brain barrier.
  • Improves drug potency – more of the ingested product is made available to the body, so lower doses are required to achieve the desired effect.
  • Reduces drug administration cost – lower doses mean lower overall drug costs.
  • Masks unwanted taste – the technology eliminates or reduces the need for sweeteners.

Lexaria has demonstrated in animal studies a propensity for DehydraTECH technology to elevate the quantity of drug delivered across the blood-brain barrier by as much as 1,900 percent, initiating additional new patent applications and opening possibilities for improved drug delivery.

Since 2016, DehydraTECH has repeatedly demonstrated, with cannabinoids and nicotine, the ability to increase bio-absorption by up to five to 10 times, reduce time of onset from one to two hours to just minutes, and mask unwanted tastes. The technology is to be further evaluated for additional orally administered bioactive molecules, including antivirals, cannabinoids, vitamins, non-steroidal anti-inflammatory drugs (NSAIDs) and nicotine.

Market Outlook

Lexaria’s ongoing research and development efforts are mainly focused on development of product candidates across several key segments:

  • Oral Cannabinoids – a market estimated to be worth $18.4 billion in 2021 and expected to reach $46.2 billion by 2025.
  • Antivirals – an estimated $52.1 billion market in 2021 that’s expected to grow to $66.7 billion by 2025.
  • Oral Mucosal Nicotine – smokeless tobacco products, a $13.6 billion market in 2018, is forecast to grow at 7.2 percent annually through 2025.
  • Human Hormones – estrogen and testosterone replacement therapies represented a $21.9 billion market in 2019, with a forecast CAGR of 7.7 percent through 2027.
  • Ibuprofen and Naproxen – NSAID sales totaled $15.6 billion globally in 2019 and are projected to reach $24.4 billion by 2027.
  • Vitamin D3 – the global market size was $1.1 billion in 2021, growing at 7 percent per year and expected to reach $1.7 billion in 2026.

Management Team

Chris Bunka is Chairman and CEO of Lexaria Bioscience Corp. He is a serial entrepreneur who has been involved in several private and public companies since the late 1980s. He has extensive experience in the capital markets, corporate governance, mergers and acquisitions, as well as corporate finance. He is named as an inventor on multiple patent innovations.

John Docherty, M.Sc., is the President of Lexaria. He is a pharmacologist and toxicologist, and a specialist in the development of drug delivery technologies. He is the former president and COO of Helix BioPharma Corp. (TSX: HBP). He is named as an inventor on multiple issued and pending patents.

Greg Downey is Lexaria’s CFO. He has more than 35 years of diverse financial experience in the mining, oil and gas, manufacturing, and construction industries, and in the public sector. He served for eight years as CFO for several public companies and has provided business advisory and financial accounting services to many large organizations.

Gregg Smith is a strategic advisor to Lexaria. He is a founder and private investor with Evolution VC Partners. He is a member of the Sand Hill Angels and held previous investment banking roles with Cowen and Company and Bank of America Merrill Lynch.

Dr. Philip Ainslie serves as a scientific and medical advisor to Lexaria. He is co-director for the Centre for Heart, Lung and Vascular Health, Canada. He is also Research Chair in Cerebrovascular Physiology and Professor at the School of Health and Exercise Sciences, Faculty of Health and Social Development at the University of British Columbia.

Lexaria Bioscience Corp. (LEXX), closed Wednesday's trading session at $2.94, up 6.9091%, on 103,139 volume. The average volume for the last 3 months is 103,139 and the stock's 52-week low/high is $2.64/$12.50.

Recent News

Pressure BioSciences Inc. (PBIO)

The QualityStocks Daily Newsletter would like to spotlight Pressure BioSciences Inc. (PBIO).

Pressure BioSciences (OTCQB: PBIO) (“PBI”) is a leader in the development and sale of broadly enabling, pressure-based instruments, consumables and specialty testing services to the worldwide biotechnology and other industries. The company today announced the initiation of an Early Access Program (effective July 1, 2022) for the use of its revolutionary Ultra Shear Technology(TM) (“UST(TM)”) platform for the processing of oil-based active ingredients into highly stable, water-soluble, long-term stable nanoemulsions. “We have announced our plans to have commercial toll-production UST-processing capacity operational on the East and West coasts of the USA by Q4 2022,” said John B. Hollister, director of sales and marketing at PBI. “Since announcing this, we have worked closely with a number of companies on formulating some of their products. As a result, the demand to serve initial contracts for pilot-scale production of nanoemulsions in nutraceuticals, cosmetics, health and beauty care, and agrochemical markets has become particularly intense and is growing. We anticipate the announcement of at least two significant relationships and contracts within these sectors during Q2 2022, for which early small-batch production capacity can be pivotal to accelerating the commercialization phase to follow.” To view the full press release, visit

Pressure BioSciences Inc. (PBIO) develops, markets and sells proprietary laboratory instrumentation and associated consumables to the life sciences sample preparation market. Sample preparation refers to the wide range of activities that precede most forms of scientific analysis. It is often complex and time-consuming, yet a critical part of scientific research. The market for sample preparation products is currently estimated at $6 billion worldwide.

The Company’s product line can be used to exquisitely control the sample preparation process. It is based on a patented, enabling technology platform called pressure cycling technology (“PCT”). PCT uses alternating cycles of hydrostatic pressure between ambient (14.5 psi) and ultra-high levels (up to 100,000 psi) to safely and reproducibly control critical biological processes, such as the lysis (breakage) of cells, the digestion of proteins, and the inactivation of pathogens.

Pressure BioSciences’ product line is led by its newly released, next-generation Barocycler 2320EXTREME instrument. Named a finalist in the prestigious 2017 R&D Awards (also known as the “Oscars of Innovation”), the Barocycler 2320EXT is already being touted by some key opinion leaders as an essential element of the $1.8 billion U.S. “Cancer Moonshot” program. For example, Professor Phil Robinson, Co-head of the cancer research center of the Children’s Medical Research Institute (Sydney, Australia), said in a recent interview: “We are collecting the whole proteome on 70,000 tumor samples from all classes where complete clinical outcome is known. Due to its unique capabilities, the Barocycler 2320EXT has become a critical part of our program. It is the primary enabler of the high-throughput component of the project. Without this step, our project simply could not be done. In fact, the Barocycler 2320EXT works so well we have just purchased two more.”

Momentum is building when it comes to the potential for using the Company’s unique PCT technology platform. Leading scientists are intrigued by Pressure BioSciences’ approach, which among other attributes, revolutionizes the process of rupturing cells (lysis) for further study, yielding superior biomolecules for investigation. The Company’s technology transcends current methods of breaking open cells, which use chemicals, blades, metal beads, or other damaging and altering methods that can ultimately adversely affect the result for researchers. Pressure BioSciences’ PCT technology utilizes customized, controlled hydrostatic (water) pressure to rupture cells in a chamber, enabling exquisitely customized levels of pressure to optimally break open different types of cells at prescribed pressure levels—something never before accomplished in a commercial setting. Using this pioneering method, the result is a truer, more legitimate sample, which boosts the efficacy of research and the quality of results. The potential impact of this technology on scientific advancement is enormous, enabling research scientists to begin their studies with biological samples of unprecedented integrity, with the potential to improve research outcomes at the earliest, most critical step. PCT can additionally inactivate pathogens (e.g., viruses, bacteria) using hydrostatic pressure, making the samples safer to study—another innovation with astronomical potential for application in a variety of markets.

The Company’s high-pressure instruments for research purposes are marketed throughout the United States, Europe, China and Japan. To date, Pressure BioSciences has installed nearly 300 PCT Systems in over 165 leading academic, government, biotech and pharma laboratories around the world. Its primary applications are in biomarker discovery, forensics, agriculture and pathology. Over 100 scientific papers have been published on the advantages of the PCT platform, which is also being used in the specialized fields of drug discovery and design, bio-therapeutics characterization, soil and plant biology, vaccine development and histology.

Impressive as their biotech business is, there is more to the PBI story. Pressure BioSciences recently received two patents in China for its novel Ultra Shear Technology (UST), a process that has potential in a wide range of industrial applications, including extending the shelf life of some food products and making two insoluble liquids (like oil in water) soluble. Patents have also been filed in many other countries worldwide. UST is a novel technique based on the use of intense shear forces generated from ultra-high-pressure valve discharge.

This important technology has the potential to play a significant role in a number of commercially important areas through its ability to create high-quality, stable nanoemulsions. Scientific studies indicate that improved absorption, higher bioavailability, greater stability, lower surfactant levels and other advantages can be achieved with nanoemulsions — all hugely important factors in the fields of nutraceuticals, cosmetics, pharmaceuticals, and in various medical products. There is an enormous opportunity in the cannabis market, since the technology can potentially reduce oil droplets containing cannabidiol (CBD) to nanoparticles, after which they can be safely suspended in a stable water solution—something many companies have endeavored to achieve without success. Researchers looking for a way to increase the bioavailability of cannabinoids in the body will find this technology a game changer.

The Company’s UST technology also has possibilities in the production of clean label foods, which are currently processed using several innovative methods, including high-pressure treatments (such as Starbucks’ Evolution line of juices). In 2015, the worldwide market for high-pressure processed (HPP) food was estimated at U.S. $10 billion. UST uses ultra-high pressures and certain valves to generate intense shear forces under controlled temperature conditions to produce nanoemulsions, and which also significantly reduces food-borne pathogens. Pressure BioSciences’ initial focus with this technology will be to evaluate UST for the production of high-quality dairy products and beverages.

Pressure BioSciences Inc. (PBIO), closed Wednesday's trading session at $1.85, up 10.7784%, on 25,110 volume. The average volume for the last 3 months is 25,110 and the stock's 52-week low/high is $1.57/$4.98.

Recent News

Mullen Automotive Inc. (NASDAQ: MULN)

The QualityStocks Daily Newsletter would like to spotlight Mullen Automotive Inc. (MULN).

Many car manufacturing companies are taking part in the 2022 Austin Auto Show where they are showcasing their electric cars. Most of the electric vehicles on the show’s floor are already limited in availability, with the spokesperson for Ford revealing that its F-150 model has more 100,000 orders, despite not having been released yet. The 2022 Niro electric vehicle by Kia is also on display. This limited production model is only sold in a number of states in specific retailers. EnergyX CEO and Founder Teague Egan has argued that the lithium scarcity in the market may be a major cause of the limited availability of these vehicles. Lithium is essential for the manufacture of all the different types of batteries for electric cars. As the raw material shortage continues to bite, electric vehicle sector players such as Mullen Automotive Inc. (NASDAQ: MULN) will have no choice but to get very creative in order to find workarounds to the supply crunch.

Mullen Automotive Inc. (NASDAQ: MULN) is a Southern California-based automotive company that owns and partners with several synergistic businesses working toward the unified goal of creating clean and scalable energy solutions. Mullen has evolved over the past decade in sync with consumers and technology trends. Today, the company is working diligently to provide exciting EV options built entirely in the United States and made to fit perfectly into the American consumer’s life. Mullen strives to make EVs more accessible than ever by building an end-to-end ecosystem that takes care of all aspects of EV ownership.

Commencement of Trading on Nasdaq

On November 5, 2021, Mullen announced its commencement of trading on the Nasdaq Capital Market.

“Today is a monumental day for Mullen Automotive. I am especially proud of our team, investors and all who have believed in Mullen and taken us to this point as a publicly traded company on the Nasdaq Capital Market,” David Michery, CEO and Chairman of Mullen Automotive, stated in the news release. “Trading on Nasdaq now opens us up to new investors, both institutional and retail shareholders, and broadens our awareness and company profile, while increasing awareness of Mullen and our technology platform and opening new opportunities in EV and beyond. The road ahead has never been brighter for Mullen, and I am proud to lead us into the future.”

The milestone came in the wake of the company’s stock-for-stock merger with Net Element Inc.

The Mullen FIVE

The Mullen FIVE EV Crossover, debuting at the Los Angeles International Auto Show (LAIAS) on November 17, 2021, embodies Mullen’s Southern California roots with an inspired design focused on two complementary Golden State themes – California landscape and California urban.

The FIVE is built on an EV Crossover skateboard platform that offers multiple powertrain configurations and trim levels in a svelte design that is Strikingly Different™ and exciting to experience in person.

Prior to the start of LAIAS, the Mullen FIVE was selected as a finalist by the LA Auto Show for Top EV SUV in the ZEVA “People’s Choice” Awards.

LAIAS provides Mullen an opportunity to display multiple variants of the FIVE model while also showcasing its powertrain, battery and charging technology. The company intends to bring the FIVE to market in 2024, and reservations are currently open here.

Mullen’s development portfolio also includes EV Fleet Vans, which it intends to bring to market in Q2 2022, and the pure electric, high performance Mullen DragonFLY.

Expansion of Manufacturing Capacity

On November 2, 2021, Mullen announced plans to expand its facility in Robinsonville, Mississippi.

Mullen’s Advanced Manufacturing and Engineering Facility (AMEC) currently occupies 124,000 square feet of manufacturing space. The total available land on the property is over 100 acres, and Mullen is moving ahead with plans to build out another 1.2 million square feet of manufacturing space to support class 1 and class 2 EV cargo vans and the Mullen FIVE EV Crossover.

On the expanded site, Mullen plans to build a body shop, a fully automated paint shop and a general assembly shop.

EV Market Outlook

The global EV market was reported to consist of 3,269,671 units in 2019, a figure that is expected to grow at a CAGR of 21.1% through 2030 to a total of 26,951,318 units worldwide. This market’s monetary value was estimated at $162.34 billion in 2019 and is expected to grow at a CAGR of 22.6%, resulting in an approximate value of $802.81 billion by 2027. The primary driver for this exponential growth is a worldwide increase in vehicle emissions regulations.

Management Team

David Michery is the CEO and Founder of Mullen and has been leading the company and its divisions since inception in 2014. With over 25 years of executive management, marketing, distressed assets, and business restructuring experience, Mr. Michery brings a wealth of relevant knowledge and expertise to the Mullen brand. He has notably created 12 trademarks so far to develop the company brand and vision.

Mr. Michery is working toward a sustainable future accessible to all by creating a suite of clean-energy electric vehicles at varied price points. With entirely U.S.-based manufacturing and operations, he is also determined to have Mullen Technologies play a role in shaping a self-sustaining local economy by creating more jobs in America.

Mr. Michery manages risks and company expectations as a pathway to success and has personally overseen several businesses that totaled over $1 billion in transactions. His key strength is the ability to be fiscally responsible and lead teams to complete projects on time and within budget. As a seasoned professional in this space, Mr. Michery has demonstrated skill in building businesses from the ground up and into successful entities that subsequently sold for hundreds of millions of dollars.

Mullen Automotive Inc. (MULN), closed Wednesday's trading session at $1.35, up 4.6512%, on 40,389,341 volume. The average volume for the last 3 months is 38.632M and the stock's 52-week low/high is $0.52/$15.90.

Recent News

Silo Pharma Inc. (OTCQB: SILO)

The QualityStocks Daily Newsletter would like to spotlight Silo Pharma Inc. (OTCQB: SILO).

Silo Pharma (OTCQB: SILO), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, has long been familiar with the potential of psychedelics. A recent article, which contains excerpts from a New York Times writeup entitled “The Psychedelic Revolution Is Coming,” documents the increased urgency to develop new therapeutics. “This urgency aligns with Silo Pharma’s mission of identifying assets to license while funding transformative research for the well-being of patients and the health care industry. Silo Pharma focuses specifically on patients suffering from largely underserved indications like post-traumatic stress disorder (‘PTSD’), fibromyalgia, Alzheimer’s, Parkinson’s, and other rare neurological disorders,” the article reads. “The company has filed four U.S. provisional patent applications and a pipeline including a research collaboration with Columbia University and UCSF; an investigator-led sponsored study with Maastricht University; an option agreement with the University of Maryland, Baltimore for patented homing peptides targeting rheumatoid arthritis; licensing for a patented novel peptide-guided drug-delivery approach for the treatment of multiple sclerosis; and upfront funding for a licensing deal for its psilocybin cancer therapeutic applications.” To view the full article, visit A new study is looking into whether autoimmunity is a trigger for Parkinson’s disease. Parkinson’s disease is a brain disorder that causes an individual to have issues with coordination, balance and walking. This progressive disorder also causes stiffness and shaking, and is known to worsen over time. Figures show that about one million individuals in America suffer from Parkinson’s disease. On a global scale, the disease is said to affect more than 10 million individuals. Thus far, research has shown that before the disease progresses to a loss in motor skills, patients may experience changes in their sense of smell, have issues with sleep and also have constipation. The team is currently focused on finding ways to use the genetic signature of the disease in memory T cells to identify individuals who may develop the illness. They hope that their findings will facilitate the development of new treatments for this debilitating disorder as well. Several companies, including Silo Pharma Inc. (OTCQB: SILO), are already searching for the next breakthrough treatment for Parkinson’s and other neurological conditions, and psychedelics could be the secret sauce that delivers those novel remedies.

Silo Pharma Inc. (OTCQB: SILO), a developmental stage biopharmaceutical company, is focused on merging traditional therapeutics with psychedelic research for people suffering from indications such as post-traumatic stress disorder (PTSD), fibromyalgia, Alzheimer’s disease, Parkinson’s disease, and other rare neurological disorders. Silo’s mission is to identify assets to license and fund research that the company believes will be transformative to the wellbeing of patients and the health care industry.

Silo is committed to developing innovative solutions to address a variety of underserved conditions. Combining Silo’s resources with world-class medical research partners, the company looks to make significant advances in the medical and psychedelic space.

Silo works to identify and partner with leading medical universities, providing the needed financial resources to develop safe therapeutic treatments while moving cutting-edge research through the clinical stage and into commercialization. The company is well-capitalized with access to additional funds as opportunities present themselves.

Silo recently engaged Donohoe Advisory Associates LLC for consulting and advisory services in connection with the potential uplisting of Silo’s common shares to the Nasdaq Stock Market.


Silo has entered into research agreements and partnerships with multiple leading medical universities.

The company is involved in a sponsored study with Maastricht University utilizing repeated low doses of ketamine and psilocybin to examine the effects on cognitive and emotional dysfunctions in Parkinson’s disease and to understand its mechanism of action. The investigator in the Netherlands is acquiring the substances for the study and will then finalize the documentation to submit to the ethics committee.

Additionally, in June 2021, Silo announced its entry into a scientific research agreement with the University of California San Francisco (UCSF). The agreement will leverage four other clinical trials being planned by the university to determine the effects of psilocybin on inflammation. The study will take place at The Translational Psychedelic Research (TrPR) Program at UCSF.

Silo also recently extended its exclusive option agreement with the University of Maryland, Baltimore (UMB) to explore a novel invention generally known as joint-homing peptides. These peptides are being developed for use in the investigation and treatment of arthritogenic processes and can be used for enhanced targeting of therapeutic agents.

This agreement includes the study of two separate peptides. The first is an option and study for the treatment of arthritis. The second is a patented licensed peptide for the central nervous system, with an initial study for MS autoimmune diseases, in addition to rheumatoid arthritis. Animal studies are underway for both initial indications relating to the UMB agreement, with the potential for studies evaluating additional indications in the future.

Finally, Silo signed an agreement with Columbia University granting it an option to license certain assets currently under development, including an Alzheimer’s disease formulation targeting NDMARs and 5-HT4Rs, as well as a prophylactic treatment for stress-induced disorders and PTSD. Both candidates are currently being tested in mice and have already provided early data.

In addition to its university partnerships, Silo entered a joint venture agreement with Zylo Therapeutics Inc. (“ZTI”) focused on the development of ketamine and psilocybin using ZTI’s Z-Pod™ technology for the transdermal time released delivery of therapeutics. In November 2021, the company announced ZTI’s reception of its first ketamine shipment and initiation of loading ketamine into its Z-Pod technology. In a news release, Eric Weisblum, CEO of Silo, called the development an “important milestone” that will help the company “study the benefits of slow-release transdermal release of Ketamine.”

Market Overview

According to Coherent Market Insights, the fibromyalgia treatment market was valued at $2.78 billion in 2018 and has a projected CAGR of 3.3% over the forecast period 2018 to 2026. Fibromyalgia is a condition that causes pain all over the body, sleep problems, fatigue, and emotional and mental distress.

The global PTSD therapeutics market is expected to reach $10.68 billion by 2026 with a CAGR of 4.5% during the forecast period from 2018 to 2026, according to a report by Credence Research. Growing prevalence of PTSD is the chief factor driving the global treatment market. Increases in events such as wars, combat, and interpersonal violence has been a major contributing factor. Other factors like growing emphasis on rehabilitation initiatives by governments for treating their war veterans has also been facilitating the increase in demand for PTSD therapeutics.

Fortune Business Insights reports the global Parkinson’s disease treatment market is predicted to grow to $8.38 billion by 2026, with a CAGR of 8.1% during the forecast period. Parkinson’s is a neurodegenerative disease of the central nervous system which primarily affects the brain, causing uncontrollable shaking and tremors, difficulties in balance and restricted body movement making it difficult for the person to function or perform a daily routine.

Management Team

Eric Weisblum is CEO and founder of Silo Pharma. He has over 25 years of Wall Street experience, most recently in the biotechnology sector. He has served on the board of Aikido Pharma and was the president of Sableridge Capital. He has a proven track record in licensing therapeutic assets and assisting in their development. He brings to the company nearly 20 years of expertise in structuring and trading financial instruments. He holds a bachelor’s degree from the University of Hartford’s Barney School of Business.

Dr. Kevin Muñoz was appointed to the Silo board of directors in October 2020. He teaches biomedical sciences and medical intervention for the Passaic County Technical Institute. He previously served as Director of Operations at Physical Medicine and Rehabilitation. He began his career with Harlem Health Promotion Center in New York City as a research assistant. He earned a bachelor’s degree from the University of Michigan and a Doctor of Medicine from Xavier University School of Medicine.

Josh Woolley, M.D., Ph.D., is a Scientific Advisor for Silo. He is an associate professor in the Department of Psychiatry and Behavioral Sciences at the University of California, San Francisco. He is also a psychiatrist on staff at the San Francisco Veterans Affairs Medical Center. He is the director and founder of the Bonding and Attunement in Neuropsychiatric Disorders Laboratory. He received both his M.D. and his Ph.D. in Neuroscience from UCSF, where he completed his psychiatry residency training.

Charles Nemeroff, M.D., Ph.D., is a Scientific Advisor for Silo Pharma. He directs the Institute for Early Life Adversity Research within the Department of Psychiatry and Behavioral Sciences as part of the Mulva Clinic for the Neurosciences. He was chair of the Department of Psychiatry and Behavioral Sciences and clinical director of the Center on Aging at the University of Miami Miller School of Medicine. He received his M.D. and Ph.D. in neurobiology from the University of North Carolina School of Medicine.

Silo Pharma Inc. (OTCQB: SILO), closed Wednesday's trading session at $0.175, up 7.4279%, on 3,879 volume. The average volume for the last 3 months is 3,879 and the stock's 52-week low/high is $0.12/$0.39.

Recent News

Sharing Services Global Corporation (SHRG)

The QualityStocks Daily Newsletter would like to spotlight Sharing Services Global Corporation (SHRG).

Sharing Services Global (OTCQB: SHRG), together with its new direct-selling travel division that offers exclusive benefits and first-class discount travel opportunities, Hapi Travel Destinations, is ideally poised as most indicators now show that travel is picking back up despite the global pandemic still impacting life in many ways. “Regardless of where travelers are heading, SHRG’s Hapi Travel Destinations is committed to helping them get there. The company is focused on offering discounted destinations with a maximized experience and works to offer ‘hapi’ experiences that inspire purpose and unity…. With a unique vision that ‘everyone deserves a hapi life with a bucket list of travel,’ the company is committed to bringing its members world-class adventures at affordable prices,” a recent article reads. “SHRG’s Hapi Travel Destinations is a travel company whose time has come. As travelers head back out in the world after a long break, they are looking for new experiences. Hapi Travel is dedicated to providing exactly that as it differentiates itself by offering unfettered access to tremendous savings and exclusive benefits to its members on a level that the industry has not seen before.” To view the full article, visit

Sharing Services Global Corporation (SHRG), formerly Sharing Services Inc., is a diversified company dedicated to maximizing shareholder value, operating through two primary subsidiaries: Elepreneurs Holdings, a direct-selling company, and Elevacity Holdings, a products company. Headquartered in Plano, Texas, SHRG markets and distributes Elevate-branded health and wellness products through an independent sales force of distributors called Elepreneurs.

Proprietary Products

SHRG’s current exclusive Elevate product offerings are marketed under the Elevacity brand, so named to signify the company’s commitment to elevating lives.

The Elevate health and wellness product line consists of nutraceutical products that SHRG refers to as D.O.S.E., which stands for dopamine, oxytocin, serotonin and endorphins – all of which are key hormones proven to promote happiness and well-being.

Elevacity brand products are carefully formulated, chosen and designed to support a single objective: elevate the happiness and well-being of the consumer.

Global Network of Elepreneurs

Elevacity products are shared and sold by a growing international network of home-based entrepreneurs, called Elepreneurs, operated by Elepreneurs Holdings. This SHRG subsidiary provides basic and advanced programs for both new and experienced entrepreneurs who are focusing on their direct-sales careers.

SHRG’s high-performing independent sales force follows the company’s Blue Ocean selling strategy, an approach that encourages individuals to seek new markets, lead, and to “stop competing and start creating.” The Blue Ocean strategy is based on the book, “Blue Ocean Strategy,” written by Professor Renée Mauborgne, who notes that “the lesson here is that the best defense is offense, and the best offense… is to make a blue ocean shift and create your own blue ocean.”

Following this selling strategy, SHRG’s Elepreneurs are taught that, rather than competing directly in a competitive, direct-selling market, they should focus on making competitors irrelevant and succeeding in an uncontested marketplace.

In addition, SHRG’s Elepreneurs use the interactive, video-based VERB sales-marketing platform developed by Verb Technology Company Inc. The app utilizes proprietary interactive video data collection and analysis technology and provides next-generation customer relationship management, lead generation, and video marketing software applications.

Continued Momentum as Industry Leader

These selling strategies have resulted in sharp and consistent revenue gains. In the company’s 10-Q filed with the SEC for the three months ended Oct. 31, 2019, SHRG reported sales of $38.8 million for fiscal Q2 2019, an increase of 116% over sales of $17.9 million reported for the comparable quarter of 2018. Consolidated gross profit jumped by $16.2 million to $27.4 million for the same period compared to Q2 2018.

SHRG’s consolidated operating earnings were $3.9 million in the fiscal quarter ended Oct. 31, 2019, compared to $866,802 for the comparable period the prior year. Consolidated gross margin also grew 70.9% for the three months ended Oct. 31, 2019, compared to 62.2% the prior year.

These numbers are continuing a trend established over the past two years. In fiscal Q1 2019, SHRG achieved revenues of $35.4 million, more than double that of the comparable period in 2018. Even earlier, the company reported sales of $85.9 million for fiscal year ended April 30, 2019. This represents a nine-fold increase, or $77.5 million jump, over the company’s revenues of $8.4 million the prior year.

These numbers bring SHRG’s sales revenues since December 2017 — when the company’s Elevate product line was released — to an impressive cumulative total of $169 million.

Preparing for Success

SHRG is well prepared to continue and accommodate for this growth. The company recently expanded its corporate footprint by moving to a 10,000-square-foot facility in Plano, Texas, that offers ample room to expand as the company grows and flourish. The larger corporate locale provides space for a growing customer service department, product fulfillment, opportunity and training rooms, as well as a video production suite.

In addition, the company has a seasoned, expert leadership team in place, led by John “JT” Thatch. Thatch was appointed president and CEO of SHRG in March 2018, bringing to the company his expertise obtained from successfully starting, owning and operating several businesses in various industries. His experience with corporate growth, acquisitions, financing and negotiation in fast-paced and flexible environments will significantly assist SHRG as the company aims to expand and increase revenues.

469.304.9400 x 201

Sharing Services Global Corporation (SHRG), closed Wednesday's trading session at $0.038, up 26.6667%, on 100,100 volume. The average volume for the last 3 months is 100,100 and the stock's 52-week low/high is $0.0295/$0.249.

Recent News

Kronos Advanced Technologies Inc. (OTC: KNOS)

The QualityStocks Daily Newsletter would like to spotlight Kronos Advanced Technologies Inc. (OTC: KNOS).

Kronos Advanced Technologies (OTC: KNOS), a revenue-generating product development and production company that has significantly changed the way indoor air is filtered and disinfected, today announced its financial closing on the acquisition of an 85,000 square-foot manufacturing campus located in Parkersburg, West Virginia. The facility, which for the past 25 years was used in the design and production of advanced electronics containing high-density circuit boards for aviation, military, industrial, and medical products, will be modified to produce advanced air purification devices and other wellness products based on Kronos’ Disease-Free living concept. “Nearly two years ago, we set into motion a strategic plan to transform Kronos from a marketing and fulfillment company, positioned within the fragmented market space of air purification, into a globally dominant consumer product design and manufacturing company,” said Kronos COO and CTO Joseph Florence. “Our vision is for Kronos to become a household-recognized, customer-centric design and manufacturing company providing products that improve the human condition by enhancing the air we breathe, the water we drink, the food we eat, and the environment we live in. This acquisition is a key foundational milestone in our transformation.” To view the full press release, visit

Kronos Advanced Technologies Inc. (OTC: KNOS) develops and sells a variety of disruptive, advanced, state-of-the-art air filtration and purification systems that fully remove harmful allergens, bacteria, viruses (including the flu), and even gasses from indoor breathing spaces, including healthcare and other settings.

Kronos’ own patented medical-grade technology is tested as the most effective clean air solution on the market. Kronos filters particles down to .0146 micron (.0146μm) – far beyond the 3 microns (0.3μm) of a traditional HEPA filter. Kronos® not only collects but destroys air pollutants. Kronos® AIR 5G® Air Purifiers use about 30,000 volts inside to actively destroy 99.99% of all airborne bacteria, mold, and virus particles.

Kronos® devices operate silently using nanotechnology to remove 100% of pollutants in a 400ft2 room (up to the whole house) and replenishes the room with pure, clean air every 15 minutes. Indoor household air is often four times more polluted than outdoor air, and Kronos air purifiers act like bionic lungs for the home and protect the people in it.

Unlike traditional HEPA systems that collect pollutants on filters which can, over time, grow mold and bacteria, Kronos’ patented technology destroys and eliminates all manner of harmful particles and deposits them on easy-to-clean collecting plates. This reduces the risk of harmful particles in the air and eliminates the need to replace costly HEPA filters every month.

The Kronos® AIR 5G® Air Purifier destroys and eliminates dust, allergens, bacteria, and even viruses. The AIR 5G® has been third party lab tested and confirmed to kill 99.87% of influenza virus in one hour.

The patented system’s five step process starts with a pre-filter screen that filters and collects hair, pet dander, etc. The air is then pulled through emitter wires which create a 30,000-volt electro field that zaps dangerous particulates. In the ionic field, charged particles are destroyed, killing bacteria and pathogens. The particles are then captured on collecting plates, removing dangerous toxins from circulation. The collecting plate is easily cleaned and reused without buying new filters. The catalytic layer is the final step in the purification process, removing odors and keeping the air fresh and pure. The AIR 5G® has Smart Control Auto Mode, which measures and displays the air quality in the room and self-adjusts fan speed based on how dirty the air is in the room. There’s also an AIR 5G® Smart App that displays the real time Air Quality Index and acts as a remote control.

The Kronos® AIR 5G® Air Purifier is offered in three models:

  • Kronos® AIR 5G® X3 air purifier combines powerful patented TPA® technology with a compact form factor up to six times smaller than other air purifiers, with washable and reusable filters.
  • Kronos® AIR 5G® X5 thoroughly wipes out dust, smoke, dander, bacteria, pollen, viruses, odors, germs, and more from the air, delivering the healthiest breathable air possible. It was developed for some of the world’s most polluted areas and is now available for use in the home. It runs completely silently, passing through five stages of purification to guarantee the cleanest possible air in homes or offices.
  • Kronos® AIR 5G® X8 delivers maximum power, more than doubling the capacity and efficiency of the Kronos X5, with CADR speeds of up to 470 CFM – enough to clean a 1,000ft2 room in just 20 minutes.

Kronos also offers the Kronos Car Air Purifier, the most advanced car air purifier with Kronos’ patented TPA® technology, and FitAir, the best personal air purifying solution that brings clean air anywhere by cleaning within 25ft2 of personal space at an airflow rate of 3x per hour.

Market Overview

The global air purifier market was valued at $10.38 billion in 2020 and is expected to reach $21.15 billion by 2027, achieving a CAGR of 10.7% over the forecast period, according to Brandessence Market Research. The market is primarily driven by the increasing concerns about both outdoor and indoor air pollution, coupled with the associated health problems.

Air pollution is one of the most prevalent concerns, due to worsening environmental condition. According to Health Effect Institute, it accounts for 4.9 million to 8.8 million deaths worldwide each year. Furthermore, as most of our time is spent is indoors, indoor air pollution remains a serious concern to individuals, as well as regulatory agencies. Particles like PM 2.5 can enter indoors through a wide range of sources including car engines, fireplaces, and coal- or natural gas and the infiltration of ambient particulates in urban areas. Even in the absence of solid fuels, indoor ventilation can build up PM 2.5 particles to a greater extent than in outdoor environments. Growing demand for portable air purification filters and systems in urban areas, increased advancements to catch key particulates like coronavirus, and increased regulatory measures to ensure safe environments for professionals in the industrial sector remain leading drivers of growth in the air purifier market.

Poor indoor air quality can cause fatigue, headache, and irritation of the eyes, throat, lungs, and nose, which can have a negative impact on worker productivity. Some air contaminants can cause asthma and other respiratory diseases.

Air purifier adoption is increasing rapidly in the U.S. to minimize health issues caused by poor air quality. Strict air quality standards, guidelines, and regulations in the U.S. are expected to have a positive impact on the market. For instance, the New Jersey Indoor Air Quality standard, NJAC 12:100-13 (2007), sets guidelines and standards related to indoor air quality during working hours in public employee-occupied buildings.

Key manufacturers are focusing on acquisitions and mergers to expand their geographical reach and strengthen their position in the market.

Management Team

Michael Rubinov, President and Head of Business Development

A seasoned hi-tech executive with 25 years of global business experience, Mr. Rubinov has served in various positions in sales, marketing, channel development and partner management. He has worked for large and global organizations such as Intel, NICE Systems, and Boeing (Defense and Security), as well as for start-up companies like Dialogic and Remunera International SA. He was appointed President and Head of Business Development of Kronos Advanced Technologies Inc. in February 2020. Mr. Rubinov holds an MBA, an MS Computer Sciences, and a BS Electrical Engineering.

Joseph L. Florence, Chief Operational Officer & CTO

A dynamic skilled leader in all aspects of business formation, evaluation, and execution, Mr. Florence brings a unique combination of Fortune 100 company experience with a lifetime of entrepreneurial experience to the Kronos team. He is a gifted visionary, possessing the unique ability to see future opportunities and make timely strategic adjustments and is naturally gifted at seeing unrecognized risk and overlooked opportunities. Mr. Florence has a proven track record of transforming companies to better align people, processes, and technologies to meet strategic goals and business metrics resulting in increased market share and profitability.

Kronos Advanced Technologies Inc. (OTC: KNOS), closed Wednesday's trading session at $0.01415, up 1.0714%, on 211,804 volume. The average volume for the last 3 months is 211,804 and the stock's 52-week low/high is $0.0111/$0.09.

Recent News

Friendable Inc. (FDBL)

The QualityStocks Daily Newsletter would like to spotlight Friendable Inc. (FDBL).

  • Acquired in January 2022, Artist Republik and FeaturedX, in conjunction with the Fan Pass Live artist platform, have created a 360 platform offering for music artists looking for independence from label control
  • Artists are not the only ones benefiting from Friendable’s offering – fans are also gaining access to their favorite artists without the boundaries implemented by traditional record labels
  • Friendable’s 360 offering allows artists to receive more revenue through fan subscriptions, ticket sales, tips, merchandise, and more
  • Since launching the 360 platform, Friendable has seen consistent (and positive) growth across social media platforms, including a larger online presence

Major limitations exist in the music industry for independent artists trying to enter and make a name for themselves. In addition to the lack of support and overwhelming control by a music label, there are overwhelming amounts of fees that result in revenue loss, at times up to 90%. These strict contracts and financial burdens often make it hard for artists to find footing in the industry and can either hinder advancement or completely quash their dreams before they can try reaching them. Friendable (OTC: FDBL) is disrupting the music industry by offering music artists the first 360 artist platform for production, distribution, and marketing. In conjunction with Artist Republik and FeaturedX, the Fan Pass Live artist platform takes gatekeepers and intermediaries out of the equation, leaving artists 100% in control of their music careers.

Friendable Inc. (FDBL) is a mobile technology and marketing company focused on connecting and engaging users through its proprietary mobile and desktop applications. Launched July 24, 2020, the company’s flagship offering is designed to help artists engage with their fans around the world and earn revenue while doing so. The livestreaming platform supports artists at all levels, providing exclusive artist content ‘Channels’, LIVE event streaming, promotional support, fan subscriptions and custom merchandise designs, all of which serve as revenue streams for each artist.

With Fan Pass, artists can offer exclusive content channels to their fans, who can use their smartphones to gain access to their favorite artists, as well as an all-access pass to all artists on the platform. Additionally, the Fan Pass team will deploy social broadcasters to capture exclusive VIP experiences, interviews and behind-the-scenes content featuring their favorite artists – all available to fan subscribers on a free trial basis. Subscriptions are billed monthly at $3.99, or about the cost of downloading a couple of songs, and VIP experiences are available at a fraction of the cost of traditional face-to-face meetups.

Friendable Inc. was founded by Robert A. Rositano Jr. and Dean Rositano, two brothers with over 27 years of experience working together on technology-related ventures.

The Fan Pass Mobile & Desktop App

Friendable Inc. launched its Fan Pass platform as a solution for artists and their fans as the COVID-19 pandemic and the associated shutdown have continued to severely hamstring the entertainment industry as a whole. Through Fan Pass, the company aims to reach artists at all levels looking to alter their touring schedules to include ‘Virtual Touring’, new revenue sources and innovative fan engagement opportunities that are expected to become permanent fixtures of artists’ touring routines moving forward.

Fan Pass creates an ecosystem that embraces fans of all kinds, feeding diehard followers and developing lasting connections with more casual supporters. Through the app, qualified artists are provided with a custom designed, exclusive ’Fan Pass Channel’ where they can invite fans and social followers from anywhere around the world to join in chats and live events – allowing fans to experience all there is to see of an artist in one place. Artists earn revenue from monthly fan subscribers, merchandise sales, tickets sold for virtual streaming events and generally from all content views or impressions on their channels. All content views and sales of every kind are reported to each artist through their dashboards, including real-time payout and earnings information.

Fan Pass’ exclusive ‘All Access VIP’ option provides fans with access to content, such as:

  • Live performances or online concerts
  • Backstage meetups before, during or after events
  • Livestreams of studio sessions
  • Behind-the-scenes footage of music video and photo shoots
  • Special interviews and one-on-one videos
  • Streams highlighting the artists’ daily lives

The Fan Pass platform is extremely intuitive, bringing each artist through a streamlined onboarding process, including building out artist ‘Channels’, scheduling LIVE events and designing special edition merchandise to be offered solely through exclusive Fan Pass merchandise stores.

“With the global pandemic disrupting the entertainment industry in such a profound way, artists have had to look to digital distribution and live virtual performances in order to maintain any earning opportunities. Fan Pass and our team are determined to provide solutions and support to all artists, their fans and the industry in general. We are excited about the opportunity we have to shape the future of virtual entertainment, revenue generation and artist/fan engagement,” Robert A. Rositano Jr., CEO of Friendable Inc., stated in a news release.

Market Opportunity

Artists rely heavily on revenue streams that are not often seen by those without intimate industry knowledge. When it comes to traditional performances, the sale of VIP/backstage or meet & greet passes to boost revenue can often become the majority of the artist’s annual tour revenue. Data provided by one of the company’s original entertainment partners, The Kluger Agency (TKA), suggests that as much as 18-23% of artists’ annual tour revenue has historically been derived from these VIP experiences.

The World Economic Forum reports that, in 2020, the six-month-plus disappearance of live music concerts is estimated to have cost “the industry more than $10 billion in sponsorships,” and individual artists are feeling the loss the most. Fan Pass is helping to bridge this gap, providing more affordable virtual VIP experiences that can be offered simultaneously to fans around the world.

While it’s free for artists to join, Fan Pass leverages a monthly subscription model paid by fans to generate revenues. These revenues are shared with all channel artists. In exchange for its platform features, live streaming tools, bandwidth, processing and handling, Fan Pass earns platform fees on each separately ticketed event, as well as splits with each artist on subscriber fees and merchandise designed and sold on the platform.

The U.S. video streaming industry is expected to hit $7.08 billion in value in 2021, with an estimated 100 million internet users watching online video content every day, according to data from The same report suggests that 45% of live video audiences would pay for exclusive, on-demand video from a favorite team, speaker or performer. Through Fan Pass, Friendable Inc. is uniquely positioned to capitalize on this opportunity.

Friendable App

The company’s second application, Friendable, is an all-inclusive platform where users can meet, chat and date. The app has exceeded 1.5 million total downloads, with over 900,000 historical registered users and more than 580,000 historical user profiles.

Friendable Inc.’s Next Phase of Growth

To facilitate its next phase of growth, Friendable Inc. is seeking an additional $1 million in equity investment, with a follow-on funding that meets or exceeds $5 million. The company intends to utilize its relationships to secure the lowest cost of capital available, as these funds will drive technology advancements, increase head count, fund marketing initiatives and secure additional celebrity talent aimed at bringing larger fan audiences to each released event. These initiatives will assist in building recurring monthly (fan) subscribers, effectively generating recurring monthly revenue for each artist, as well. The next phase of growth is expected to play a key role in accelerating the company’s download and conversion of data for subscription revenue and merchandise sales.

The company’s primary goal is to establish Fan Pass as a premier brand and mobile platform dedicated to connecting and engaging users around the world. In support of this goal, it has entered into a partnership with Brightcove targeting OTT platform expansion, including leaders such as iOS, Android, Apple TV, Android TV, Roku and WWW.

In the highly competitive video streaming market, Friendable Inc. has tapped into an unmet demand from today’s ever-present ‘omni-users’ for constant contact with celebrities and influencers. Via Fan Pass, the company offers investors an opportunity to gain a stake in an organization catering to this new breed of omni-users and their influencers.

The application’s potential is clearly illustrated by the interest it has generated in recent weeks. From September 4 to October 12, the Fan Pass platform added 246 new artists, accounting for a 410 percent increase in just six weeks.

“We are extremely encouraged by the ongoing swell of interest as the value of our Fan Pass platform continues to resonate in the artist community,” Friendable CEO Robert A. Rositano Jr. stated in a news release. “We believe the live streaming functionality, our full-circle offering and diverse revenue opportunities the platform offers will continue to drive exponential growth as management remains focused on building long-term shareholder value.”

Management Team

Robert A. Rositano Jr. is the co-founder and CEO of Friendable Inc. He oversees the daily management and operational duties of all areas of the business. He has over 20 years of experience as a serial entrepreneur, bringing in over $60 million in liquidity events for the companies he has created or managed. Before starting Friendable Inc. with his brother, Rositano was a founding member of the internet’s first IPO, Netcom Online Communications Inc. It was sold to ICG, then to EarthLink in 1995. He has been a co-founder of several successful ventures, including Simply Internet Inc., and America’s Biggest Inc., among others. He also authored one of the first web directories for MacMillan Publishers.

Dean Rositano is the co-founder and Chief Technology Officer of Friendable Inc. He handles the day-to-day operations and guides the technical direction of the company. He has over 15 years of executive management, financial management, high technology operations and internet architecture experience. Before co-founding Friendable Inc., Rositano co-founded several other companies, including Checkmate Mobile Inc. and Latitude Venture Partners LLC, among others.

Friendable Inc. (FDBL), closed Wednesday's trading session at $0.0006, even for the day, on 40,285,396 volume. The average volume for the last 3 months is 40.285M and the stock's 52-week low/high is $0.000495/$0.0209.

Recent News


The QualityStocks Daily Newsletter would like to spotlight SRAX Inc. (NASDAQ: SRAX).

SRAX (NASDAQ: SRAX), a financial technology company that unlocks data and insights for publicly traded companies through Sequire, its SaaS (“SaaS”) platform, has announced that it plans on reporting its 2021 annual filing shortly. The company noted that certain accounting matters had delayed its 10-K filing, but those issues have been resolved, and the company anticipates completing the filing as soon as possible. As a result of the delay, the Nasdaq Stock Market LLC had notified the company that it was no longer in compliance with Nasdaq Listing Rule 5250(c)(1) requiring listed companies to file required periodic financial reports with the Securities and Exchange Commission (“SEC”) in a timely manner. The notice has no immediate impact on SRAX’s listing on the market, and the company has 60 days to submit a plan to regain compliance, which may be unnecessary because the company is working diligent to file the required Form 10-K within the allotted time period. To view the full press release, visit

SRAX Inc.'s (NASDAQ: SRAX) is a digital marketing and consumer data management technology company. SRAX’s technology unlocks data to reveal brands’ core consumers and their characteristics across marketing channels.

Through its BIGtoken platform, SRAX has developed a consumer-managed data marketplace where people can own and earn from their data, thereby providing everyone in the internet ecosystem choice, transparency and compensation.

SRAX’s tools deliver a digital competitive advantage for brands in the CPG, automotive, investor relations, luxury and lifestyle verticals by integrating all aspects of the advertising experience, including verified consumer participation, into one platform.

SRAX Verticals

  • SRAX Core: SRAX Core is a custom digital media management platform that enables brands and agencies to surpass the challenges of omnichannel marketing campaigns. It offers one comprehensive dashboard to manage digital media campaigns, inventory and reporting.
  • SRAX Social: SRAX Social is a free social media management tool that makes it easy for brands, agencies and individuals to grow their digital presence. It offers free and unlimited users, Facebook auto boosting, and a custom analytics dashboard. Its managed services team can also build and execute marketing plans for your unique specific needs.
  • SRAX IR: SRAX IR unlocks stock buyers’ behaviors and trends for issuers of publicly traded companies. The platform provides insights on shareholders and market makers, investor relations management, shareholder outreach tools and data-driven marketing.
  • SRAX Auto: SRAX Auto unlocks auto intenders’ data to create measurable connected experiences on the road to purchase. It offers proprietary auto intender profiles, multi touchpoint communication and custom location-based ads.
  • SRAX Shopper: SRAX Shopper delivers a cross channel, premium digital experience at scale to high value shopper audiences. It offers proprietary shopper profiles, cost per click pricing, and custom text and add to cart ad units.
  • SRAX Lux: Launched in June 2019, the SRAX Lux platform targets and reaches luxury consumers at luxury retail stores, high-end art, music, film, fashion and sports events, across all consumer devices.


BIGtoken, available for download on the App Store and Google Play, revolutionizes data collection. BIGtoken is a platform that creates a secure and transparent environment for consumers to own and earn from their data. To date, there are 15.9 million BIGtoken registered users worldwide.

The optimization and monetization of data is a multibillion-dollar business. Worldwide spending on big data and business analytics solutions reached $166 billion in 2018 and is projected to surge to $260 billion by 2022. BIGtoken’s consumer vision is committed to delivering choice, transparency and compensation to the individual.

Through BIGtoken, consumers earn rewards when they opt into sharing their data and when that data is purchased. Consumers decide what data is shared, who can buy it and how it’s used, and advertisers reach real, responsive audiences. The benefit of this is two-fold: consumers know how their data is used and advertisers gain verified consumer data for targeting.

Users of the BIGtoken app can officially be paid in cash or gift cards in exchange for giving brands access to their anonymized data, answering questions, checking into locations, recruiting new members, and more. Users can deposit their earnings directly into PayPal accounts or be paid through gift cards from favorite retailers such as Walmart.

SRAX has also partnered with several high-profile, nonprofit associations to provide BIGtoken users the ability to donate their earnings. Partnerships include the American Heart Association, dedicated to fighting heart disease and stroke; HealthCorps, which helps high school students make better choices about health and physical fitness; and the ALS Association, which recently launched its Challenge Me campaign.

International Expansion

BIGtoken is formally launching into several international markets and partnering to foster local support. SRAX recently signed a joint venture with the Yash Birla Group to launch BIGtoken in India. Based in Mumbai, the Yash Birla Group, one of India’s largest conglomerates, has diversified interests in consumer and industrial products.

The partnership will bring BIGtoken’s platform to India, which has a digital population of 627 million. The India digital advertising market is $3.6 billion and is set to grow at a compound annual growth rate of 32%, making it one of the largest growing digital ad markets in the world.

SRAX Mexico is led by Moe Avitia, who has more than 18 years of experience in business development and building high-tech teams. SRAX Mexico includes a team of 90 employees, including 70 engineers.

BIGtoken Europe is currently evaluating data centers in individual countries for privacy laws.


Christopher Miglino is CEO and founder of SRAX. He has spent the past 20 years working in the digital advertising space and has successfully launched and sold two internet companies. Both of these companies were sold to publicly traded companies on the NASDAQ. He has a detailed understanding of how technology interacts with brands.

Kristoffer Nelson is COO of SRAX and a founding member of BIGtoken. With over 15 years of technology and creative business experience, Nelson has been a guest speaker for Loyola Marymount University among other academic institutions, the National Association of Broadcasters, the IAB and numerous other professional and media organizations.

SRAX Inc. (NASDAQ: SRAX), closed Wednesday's trading session at $3.665, off by 5.0518%, on 258,941 volume. The average volume for the last 3 months is 258,941 and the stock's 52-week low/high is $3.53/$7.29.

Recent News

Delic Holdings Corp. (CSE: DELC) (OTCQB: DELCF)

The QualityStocks Daily Newsletter would like to spotlight Delic Holdings Corp. (CSE: DELC) (OTCQB: DELCF).

  • Delic is a leader in new medicines and treatments that offers education, research, high-quality products, and treatment options
  • The company is on a mission to help heal the mental health pandemic, which has been triggered and worsened by the COVID-19 disease
  • Delic operates the largest, most profitable chain of wellness clinics providing ketamine treatments in the United States
  • With 13 clinics already in operation, Delic is eyeing expansion as it seeks to ensure 60-70% of Americans are within a 45-minute drive to its clinics

The latest data from the World Health Organization (“WHO”) shows that the COVID-19 pandemic has triggered a 25% increase in the number of cases of anxiety and depression globally. Caused by multiple exacerbating factors, including loneliness, suffering and death, fear of infection, financial worries, and grief, this increased prevalence has also coincided with the substantial disruption in mental health services, creating a gaping hole in the care of people leaving with these conditions ( Delic Holdings (CSE: DELC) (OTCQB: DELCF), a leader in new medicines and treatments for a modern world, has stepped up its efforts as it looks to fill the gaps exposed by COVID-19’s battering of the health sector. “Our mission is to heal the planet. We want to help heal the mental health pandemic. I don’t think we could have come about at a better time. I think it’s necessary; I wish it weren’t so necessary, but it is, and so, when people need that help, we are here to provide it,” Delic Co-founder and CEO, Matt Stang, said in a January interview ( Delic Holdings (CSE: DELC) (OTCQB: DELCF), the leading psychedelic wellness platform, through its subsidiary and the largest ketamine therapy provider in the United States, Ketamine Wellness Centers (“KWC”), recently announced the expansion of its treatment options to include SPRAVATO(R) nasal spray for adults. The first FDA-approved ekestamine nasal spray for adults, SPRAVATO is made explicitly for treatment-resistant depression (“TRD”) along with the treatment of depressive symptoms in adults with major depressive disorder (“MDD”) with suicidal thoughts or actions. A recent article reads, “While making the announcement, Kevin Nicholson, the CEO of KWC and COO of Delic, noted that the introduction of SPRAVATO underscores KWC’s commitment to providing clinically-backed, accessible, and affordable treatments to patients nationwide. He further pointed out that the company’s dedication to offering the highest quality service available, coupled with its vast network of ketamine clinics, allows it to serve more patients than any other ketamine therapy provider.” To view the full article, visit Various studies have found that psychedelic treatments have the potential to treat mental health conditions such as anxiety and depression, among others. This, coupled with the ineffectiveness of current treatments, has made investing in psychedelics appear even more lucrative. Before you invest in psychedelics, you should take steps to mitigate your risks and do your own research. Remember to always be responsible with your money when investing in any sector. The risks above notwithstanding, savvy investors have a large pool of potential possibilities in which to invest, including Delic Holdings Corp. (CSE: DELC) (OTCQB: DELCF). They need to ensure that they perform their due diligence preceding any investment activity.

Delic Holdings Corp. (CSE: DELC) (OTCQB: DELCF) is the leading psychedelic wellness platform, committed to bringing science-backed benefits to all and reframing the psychedelic conversation. The company owns and operates an umbrella of related businesses, including trusted media and e-commerce platforms like Reality Sandwich and Delic Radio; Delic Labs, the only licensed entity by Health Canada to exclusively focus on research and development of psilocybin vaporization technology; Meet Delic, the premiere psychedelic wellness event; and Ketamine Infusion Centers, one of the largest ketamine clinics in the country.

Delic is backed by a team of industry and cannabis veterans and a diverse network, whose mission is to provide education, research, high-quality products, and treatment options to the masses. Its founders helped build the multi-billion-dollar cannabis industry and aim to do the same in psychedelics as it follows a similar path toward legalization. In its quest to advance the new psychedelic renaissance upon us, Delic has become the pioneer in its field, creating an ecosystem of opportunities by investing in cutting-edge ideas.

The Vancouver-based company was formed in 2019 to address the growing interest in psychedelic wellness backed by science. Delic was the ‎first psychedelic umbrella platform. It is currently a trusted source for those interested in ‎psychedelic culture, education, treatments, and more.

While other emerging companies focus on patent medicine and big pharma for substances limited by government regulation, Delic is blazing a unique trail. It identifies ancillary and fully legal opportunities like IP, new media, live events, ketamine clinics (with the ability to offer additional psychedelic treatments once legalized, and large-scale production and brings them under its big tent of resources and reach.

The Big Problems Delic Is Addressing

  • Fifty percent of Americans will meet the criteria for a mental health condition sometime in their lifetime. The FDA has approved psilocybin therapy as a breakthrough therapy for depression.
  • Every 40 seconds, someone in the world commits suicide. Ketamine has been shown to decrease thoughts of suicide significantly. In 2019, the FDA approved esketamine as a fast-acting antidepressant.
  • Traditional palliative care methods do not eradicate end-of-life (EOL) anxiety. LSD and psilocybin have been shown to reduce EOL anxiety for terminally ill patients. Eighty percent of terminally ill patients with psilocybin sessions experienced significant reductions in depression and anxiety.
  • Approximately 50 million people in the U.S. are addicted to some tobacco product. Research shows that psilocybin is helping people quit smoking.

The Delic Ecosystem

The Delic Ecosystem covers three main areas: media, health, and science. The media focus is educating and motivating the masses through a variety of digital platforms, like Delic’s Reality Sandwich digital magazine, a free public education platform providing psychedelic guides, news and ‎culture (1.4+ million page views in 2020 and 54k social media followers across all platforms); Meet Delic, the first-ever psychedelic wellness summit and the premier psychedelic wellness event based in Las Vegas (over 2,000 live attendees and 5,000+ email subscribers); and Delic Radio (over 43 episodes and 100k total streams). Delic has also been featured in numerous media outlets like Forbes, NBC News, The Joe Rogan Experience, Daily Beast, High Times, and The Dr. Drew Podcast.

The focus of Delic’s health operations is the most accessible psychedelic treatments that can help billions of people live happier lives. Delic does this through one of the largest ketamine clinic chains in the country, Ketamine Infusion Centers (KICs), a limited liability corporation formed under the laws of Arizona that runs three ketamine clinics located in Bakersfield, California, and Phoenix, Arizona. Its management team has over 15 years of experience in the clinic and medical space, scaling and operating over 20 clinics, with a plan to open 10 more clinics in the next 18 months. Together, these clinics have overseen 4,000+ treatments delivered to date.

The focus of Delic’s science operations is developing IP and advanced extraction and testing facilities that are the backbone of the legal market. Delic carries this out through Delic Labs, a licensed cannabis and psilocybin research laboratory based in Vancouver. It’s the only entity licensed by Health Canada to exclusively focus on research and development of psilocybin vaporization technology.

Founded by award-winning chemists, Delic Labs focuses on extraction optimization, analytical testing, and chemical process development to advance the cannabis and psilocybin industries. Health Canada gave it a Section 56 Exemption to work with psilocybin compounds, allowing the company to possess and research these products for development and quality control before they hit the market.

Latest Acquisition – Homestead Book Company

On March 4, 2021, Delic announced its acquisition of Seattle-based Homestead Book Company. Homestead is a legacy counterculture distributor of psychedelic media. It’s also the creator of one of the first self-contained psilocybin mushroom grow kits.

The acquisition of Homestead is an exciting one, as it shows how Delic is increasing accessibility to this nascent industry within regulated jurisdictions. Homestead has sold tens of thousands of mushroom kits globally and was one of the earliest distributors for High Times and many other counterculture publications.

The Homestead acquisition allows Delic to increase its product offerings on its website, Reality Sandwich, which recently hit a record for average monthly traffic of over 200,000 unique visitors and over 2.6 million active readers in 2020.

Market Outlook

The psychedelic renaissance is here. Just in time to help address the global mental health crises, plant medicines have the potential to help billions of people live happier lives. Thanks to university-led and FDA-approved studies, North America is leading the way in advancing an industry as psychedelics are becoming accepted globally for therapeutic, medical, and recreational use. Here are some statistics:

  • 32 million people in the U.S. have used psychedelics at least once
  • 17% of all American adults between 21 and 64 have used psychedelics at least once
  • $500 billion is spent in the U.S. every year on prescription drugs
  • $238 billion is spent in the U.S. every year on mental health treatments and ancillary services
  • The anxiety disorder and depression treatment market is estimated at $16 billion
  • $187.8 billion was spent in 2013 on mental health and substance abuse disorders

Management Team

Delic Co-Founder and CCO Jackee Stang was an executive at High Times, a leading counterculture publication that became the voice for the cannabis industry. The monthly magazine had a circulation of over 500,000 copies per issue. Its website attracted 500,000 to five million users each month by 2014.

Likewise, company Co-Founder and CEO Matt Stang was a previous owner and operator of High Times, a position from which he played an instrumental in legalizing cannabis in multiple states and launched the Cannabis Cup in America. After interacting with the cannabis community for two decades, he helped found Delic in 2019 as one of the first psychedelic corporations. He shapes the company’s vision and path using his expertise in branding, marketing, business development, and product viability.

Delic’s VP of Business Development, John Coleman, Ph.D., is a former president of Anandia Labs, a biotech company focused on genetics and analytics. Having experience in both science and business, Dr. Coleman is well-equipped to lead Delic’s business development efforts as it strives to enter new vertical markets.

Zak Garcia is the company’s Chief Marketing Officer. He was the former CMO of Bulletproof Inc., maker of the well-known Bulletproof Coffee brand. Mr. Garcia is a marketing and leadership strategist who helped grow Bulletproof Coffee to over $250 million in revenue.

Delic Holdings Corp. (DELCF), closed Wednesday's trading session at $0.0659, off by 7.1831%, on 53,974 volume. The average volume for the last 3 months is 53,974 and the stock's 52-week low/high is $0.03308/$0.398.

Recent News

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers

The QualityStocks Sponsored News

The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal

The QualityStocks Sponsored News

The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal

The QualityStocks Sponsored News

The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.